Bioactive substances and uses thereof

CN118973586APending Publication Date: 2024-11-15AREPA IP LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030776.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-28
Filing Date
2023-02-28
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing MAO inhibitors have side effects in the treatment of depression and Parkinson's disease, such as hypertension and suicidal thoughts, and food and drug interactions lead to adverse reactions, lack of selectivity and safety.

Method used

Using pyropodosin and its esters as inhibitors of MAO-A and MAO-B, a natural, reversible selective inhibitor is provided by consuming blackcurrant juice or extracts, to avoid the toxic accumulation of dietary monoamines. Reduce the risk of side effects.

Benefits of technology

实现了对MAO-A和MAO-B的有效抑制,降低了血压和情绪相关风险,提供了安全且有效的治疗帕金森病和抑郁症的新途径,且与传统药物相比具有更少的不良 reaction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973586A_ABST
    Figure CN118973586A_ABST
Patent Text Reader

Abstract

The present invention relates generally to stringosine and esters thereof and their novel use as MAO inhibitors and as treatment or prevention of various related conditions associated with MAO activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention broadly relates to sarmentosin and esters thereof and their novel uses as MAO inhibitors and for the treatment or prevention of various related conditions associated with MAO activity. Background Art

[0002] Monoamine oxidase (MAO) is an enzyme that catalyzes the oxidative deamination of amines such as dopamine and serotonin. The enzyme is expressed as two isozymes (MAO-A and MAO-B). Monoamine inhibition can be reversible or irreversible and can act non-selectively, affecting both isoforms, or selectively, affecting only one isoform. They play a major role in the metabolism of both dietary and endogenous monoamines (Yamada and Yasahura, 2004).

[0003] MAO enzymes are of interest as targets for nutraceutical, functional food and drug discovery because, for example, MAO-A is involved in psychiatric conditions and depression, while MAO-B is associated with neurological disorders such as Parkinson's disease and Alzheimer's disease.

[0004] In 1994, Delumeau et al. concluded from various human and animal studies that MAO inhibitors appear to improve cognitive function and help prevent cognitive disorders such as Alzheimer's disease, and therefore such inhibitors, once identified, present real therapeutic benefits due to their cognition-enhancing properties.

[0005] A further review by Zhiyou Cai in 2014 highlighted various MAO inhibitors that could be presented as therapeutic agents for Alzheimer's disease.

[0006] A further review by Carradoni et al., 2018 highlighted a range of MAO inhibitors in the patent literature from 2015-2017, including many newly synthesized and naturally occurring compounds derived from plant materials.

[0007] For example, phenelzine is an irreversible, non-selective MAO inhibitor that inhibits both MAO-A and MAO-B for up to three weeks.

[0008] In contrast, toloxatone, a reversible inhibitor of MAO-A, inhibited MAO-A for only six hours, after which activity returned to baseline values.

[0009] Selective reversible inhibitors are preferred because they avoid the toxic accumulation of dietary monoamines in the digestive tract, and if this continues for a prolonged period of time, tyramine can accumulate to dangerous levels, enhancing hypertensive crises. Therefore, it is important to identify reversible and / or selective MAO inhibitors.

[0010] Isocarboxazid, phenelzine, and tranylcypromine appear to have fairly comparable properties (Mallinger and Smith 1991). They are readily absorbed and reach peak concentrations within 1-2 hours. Elimination is also rapid, with half-lives ranging from 1.5 to 4 hours (particularly short for tranylcypromine).

[0011] Moclobemide is a newer MAO inhibitor drug that is easily absorbed and reaches peak plasma concentrations in about 1 hour. It is rapidly and completely metabolized, with an elimination half-life in the range of 1-3 hours.

[0012] Deprenyl (also known as selegiline) is a MAO-B inhibitor drug that has efficacy in treating depression and Parkinson's disease at doses of 1.25 mg to 10 mg per day. However, there can be significant side effects, including suicidal thoughts and high blood pressure.

[0013] In fact, many MAO inhibitor drugs are no longer beneficial for treating depression due to side effects from adverse drug and food interactions. Their primary use remains in treating Parkinson's disease.

[0014] As yet another example, US Pat. No. 8,367,121 B2 describes a nutraceutical-based approach to attenuating the processes leading to Parkinson's disease, relying in part on the selection of known MAO inhibitors (see paragraphs 0045-0047).

[0015] Due to the role of MAO in regulating dopamine and serotonin, the Mayo Clinic website ( Link ) also highlights MAO inhibitors as a useful tool for improving mental health, mood, or addressing conditions such as depression or anxiety. Various MAO inhibitors have been approved by the FDA, including isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Emsam), and tranylcypromine (Parnate).

[0016] Studies of different sources such as cigarette smoke and coffee have found that a class of amines known as beta-carboline alkaloids are inhibitors of MAO (Herraiz, 2007).

[0017] A Madrid-based research team has shown that many fruits and juices / extracts contain β-carbolines (βC) (Herraiz, 2006, 2018). When they compared a range of βCs, they found potent MAO activity in some of them.

[0018] There is some supporting evidence for the benefits of anthocyanin-rich blackcurrants on mood and cognition. Two studies have been published showing the effects of acute blackcurrant (Ribes nigrum) supplementation in healthy people.

[0019] Blackcurrant juice is rich in anthocyanins and other flavonoids. Although these phenolic compounds have been shown to have some MAO inhibitory activity, there may also be other unidentified components that may confer additional, potentially more effective MAO inhibitory activity and may therefore be of commercial and therapeutic importance. Watson et al. 2015 emphasized that there was no significant MAO-B inhibition after consumption of anthocyanin-rich blackcurrant extract, indicating that removal or degradation of unknown bioactive substances may be responsible for most of the MAO activity. In fact, it has been considered for some time that some βC in blackcurrant may be a strong candidate for the MAO inhibitory activity sometimes observed in blackcurrant juice (Budzikiewicz, 1994 and Herraiz, 2006, 2018).

[0020] In particular, there is real interest in identifying naturally occurring compounds in fruits that have MAO inhibitory activity, which can then be utilized, isolated, protected, extracted, synthetically replicated, or recombinantly produced / expressed by cell fermentation, or the levels of which can be increased in fruits or juices via selective breeding or other known genetic modification techniques.

[0021] It is an object of the present invention to address the above problems or at least to provide the public with a useful choice.

[0022] All references cited in this specification, including any patents or patent applications, are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicant reserves the right to challenge the accuracy and relevance of the references. It should be clearly understood that although a number of prior art publications are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art in New Zealand or any other country.

[0023] Throughout this specification, the word "comprise" or variations thereof (such as "comprises" or "comprising") will be understood to imply the inclusion of stated elements, integers or steps, or groups of elements, integers or steps, but not the exclusion of any other elements, integers or steps, or groups of elements, integers or steps.

[0024] Further aspects and advantages of the invention will become apparent from the ensuing description which is given by way of example only. Summary of the invention

[0025] According to a first aspect of the present invention, there is provided use of ophiopogonis glycoside or an ester thereof for inhibiting monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B).

[0026] According to a first aspect of the present invention, there is provided the use of ophiopogonis glycoside or its ester for preventing or treating diseases or conditions associated with MAO-A or MAO-B enzyme activity, or for maintaining or improving non-clinical cognitive states or conditions associated with MAO-A or MAO-B enzyme activity.

[0027] According to another aspect of the present invention, a composition formulated as a food or beverage, a pharmaceutical composition, a nutritional product or an extract from a plant material is provided, wherein when the composition is used to inhibit monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B), the composition comprises cyperus rotundus or its ester.

[0028] According to another aspect of the present invention, there is provided the use of ophiopogon glycoside or its ester, or plant materials, extracts or compositions containing them, in the manufacture of a medicament for inhibiting monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B) in a person in need thereof.

[0029] According to another aspect of the present invention, a method for inhibiting monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B) is provided, which is carried out by administering an effective amount of clematis glycoside or its ester, or a plant material, extract or composition containing them to a person in need.

[0030] According to another aspect of the present invention, there is provided a blackcurrant fruit, blackcurrant juice, extract or isolate, which, when used for inhibiting MAO-A or MAO-B, comprises an effective amount of calendula glycoside or an ester thereof.

[0031] As will be discussed and illustrated further below, a key aspect of the present invention is the use of the newly identified clematisin and its esters as inhibitors of MAO-A and / or MAO-B. To the best of the applicant's knowledge, this important and unexpected activity of clematisin or its esters was previously unknown. Surprisingly, as expected, the MAO inhibitory activity in blackcurrant was demonstrated to be independent of anthocyanins / polyphenols and independent of β-carbolines. This presents great potential for clematisin and its esters as bioactive substances to be used in their purified form, or as part of a product using a natural source (such as blackcurrant) (ensuring retention of the bioactive substance), as a new way to inhibit MAO-A and / or MAO-B and many clinical and non-clinical diseases and conditions associated with these enzymes. Another key advantage of these bioactive substances is that they occur naturally and do not show adverse effects like other commercially developed MAO inhibitors. clematisin and its esters also appear to be reversible MAO inhibitors. The inventors have discovered for the first time the significant MAO activity in blackcurrant, especially produced by these bioactive substances, and have therefore exploited this specific use within blackcurrant or other sources for MAO inhibition, or to enhance, concentrate, fortify or protect clematisin to enhance the use, efficacy or effect. It also presents new possibilities for purifying clematisin in extracts or isolating as a fully purified bioactive substance for new uses, and the opportunity to synthetically manufacture bioactive substances for beneficial uses. The invention will be further discussed in the preferred embodiments and specific embodiments below.

[0032] definition

[0033] Throughout this specification, the term "glucosidin" should be considered to mean a gamma-hydroxynitrile glycoside (chemical name: 4-(β-D-glucopyranosyloxy)-2-(hydroxymethyl-2-butenenitrile)) or a derivative thereof as shown in the following general chemical structure:

[0034]

[0035] Throughout the present invention, the term "nigrumin ester" or "ester thereof" should be taken to mean nigrumin-p-coumaric acid ester, nigrumin caffeic acid ester and / or nigrumin ferulate ester or derivatives thereof as shown in the following general structure. These are phenolic acid derivatives of nigrumin.

[0036]

[0037] R = H Niglumite-p-coumarate (glyc = glucose)

[0038] R=OH Niglumecaffeate (glyc=glucose)

[0039] R = OMe nigromatine ferulate (glyc = glucose)

[0040] Throughout this specification, the term "extract" should be deemed to mean a preparation containing clematisin or its ester obtained, separated, removed, purified or otherwise extracted from a selected source in a more concentrated form or a more purified form than in its naturally occurring form. For example, the extract can be in liquid form, such as juice, juice concentrate, or in a dry form, such as a powder, tablet or capsule. The extract may contain other biologically active substances or components from the selected source, or may be combined with other extracts, ingredients or products as desired. Alternatively, the extract containing clematisin can be in a fully purified or semi-purified form to the extent that it becomes a purified isolate and is still considered an extract for the purposes of the present invention.

[0041] Throughout this specification, the term "composition" should be considered to mean a combination of cyperus rotundus or its esters together with other ingredients or components in the form of a mixture. Without departing from the scope of the present invention, the composition can be, for example, in the form of food or beverage, pharmaceutical formulation, nutritional product, supplement or natural extract, etc.

[0042] Throughout this specification, the term "plant material" should be taken to mean any biological plant, including roots, leaves, seeds, seedlings, fruits, stems and the like.

[0043] Throughout this specification, the term "effective amount" should be taken to mean an amount of a compound that, when administered to a human or other mammal to improve, treat, prevent or delay a state, disorder or condition, is sufficient to affect such treatment. Of course, the "effective amount" may vary based on the compound, the particular condition and its severity, and the age, physical condition or weight of the mammal to be treated. Preferred effective amounts, including dosages, are discussed further below.

[0044] Throughout this specification, the term "monoamine oxidase" or "MAO" enzyme should be taken to mean an enzyme that catalyzes the oxidative deamination of amines such as dopamine and serotonin. The enzyme occurs as two isozymes (MAO-A and MAO-B).

[0045] Throughout this specification, the term "MAO inhibitor" should be considered to mean a class of chemicals, drugs, substances, extracts or biologically active substances that have partial or complete inhibitory activity on one or both monoamine oxidases, namely monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). This inhibition may be reversible or irreversible.

[0046] Throughout this specification, the term "nootropic agent" should be taken to mean a substance that improves or supports cognition, memory and / or facilitates learning.

[0047] Preferred Implementation

[0048] MAO inhibitory activity

[0049] Preferably, ophiopogonis glycoside, its esters or extracts containing them provide reversible MAO inhibition.

[0050] The MAO-B inhibition profile of blackcurrant juice has remarkable similarities to pharmacologically reversible MAO-B specific inhibitors such as lazabemide, which show rapid inhibition of MAO-B in platelets of >90% at 30 min post-dose following administration of a 100 mg dose of lazabemide, with maximal inhibition resolved at 16 h post-dose and full recovery of enzyme activity at 48 h post-dose (Dingemanse et al., 1997).

[0051] Advantageously, while exhibiting MAO inhibition similar to that of pharmaceutical drugs, blackcurrant supplementation has not shown deleterious side effects from its MAO inhibition (Braakhuis et al., 2020) and appears to advantageously provide reversible inhibition of the MAO enzyme. In addition, blackcurrant fruit, extracts from blackcurrant, or cyperus rotundus extracted or isolated from blackcurrant also appear to be particularly advantageous, as the strong safety history of blackcurrant as a food further suggests that cyperus rotundus itself will have a safety profile as a MAO inhibitor. In contrast, very few MAO inhibitor drugs are still used due to safety profiles. To the best of the inventors' knowledge, laxabemide has never been marketed.

[0052] Preferably, cyperitoside or its ester has both MAO-A and MAO-B inhibitory activity. This is supported and discussed in Example 2.

[0053] Having activity against both MAO enzymes can be very beneficial because they have strong affinities for different substrates. MAO-A shows greater affinity for hydroxylated amines such as norepinephrine and serotonin, while MAO-B shows greater affinity for non-hydroxylated amines such as benzylamine and β-phenylethylamine (PEA). In addition, dopamine and tyramine show similar affinities for each enzyme form, meaning that it may be advantageous to inhibit both to regulate their availability.

[0054] Composition and form

[0055] The composition may be in various forms without departing from the scope of the invention.

[0056] Preferably, cyperus rotundus or an ester thereof is in a plant material, extract or composition.

[0057] Particularly preferred formats are beverages or drinks, or powdered supplements; however, many other options are readily apparent to those skilled in the art.

[0058] Preferably, cleometoside or its ester is provided in a food or beverage.

[0059] More preferably, the food or beverage is based on blackcurrant fruit, blackcurrant juice, blackcurrant extract (liquid or powder form) or the like. Similarly, it will be appreciated that any other fruit source containing calendula glycoside or its esters is suitable. Alternatively, calendula glycoside may be extracted, isolated or synthetically prepared and then added to any such juice or composition type without departing from the scope of the present invention.

[0060] Since the inventors have identified the presence and MAO inhibitory activity of cyperoside and its esters in blackcurrant fruit (and extracts thereof), there is a strong commercial preference to exploit the existing biological activity in blackcurrant-based or blackcurrant-containing products for this new use. It will be appreciated that cyperoside or its esters at existing levels may be used, or further fortified, concentrated, enhanced with additional amounts of cyperoside.

[0061] Alternatively, the spatholobiside or ester thereof is provided in a nutraceutical or therapeutic form, such as a powder, tablet or capsule. Likewise, these forms may be derived from or contain blackcurrant material.

[0062] As previously emphasized, in another embodiment, whole fruit or part thereof or whole plant material or part thereof (eg blackcurrant) containing the calendula officinalis or its ester is used to achieve the new uses or methods described herein.

[0063] Alternatively, calendula officinalis or its ester is provided as an extract from a plant source.

[0064] Preferably, the extract is a polar fraction or component extracted from cleometrium truncatum from a selected source.

[0065] Preferably, the extract is non-polyphenolic.

[0066] Preferably, the extract containing MAO inhibitory activity derived from euphorbia pulegosae or its ester further contains βC.

[0067] Preferably, the extract is a juice or a concentrated form thereof.

[0068] More preferably, the juice extract is from blackcurrant fruit.

[0069] In yet another embodiment, those skilled in the art will appreciate that the present invention can be utilized by developing new plant varieties that have greater than normal or naturally occurring levels of clematisin or one of its esters. For example, the plant variety can be a black currant plant (River Currant) that already has naturally occurring (albeit at relatively minimal levels) clematisin and its esters, which is then selectively bred to have increased levels of the bioactive substance and then used for the applications described herein.

[0070] Preferred concentrations of scutellaria baicalensis glycosides or esters in extracts or compositions

[0071] Preferably, the extract or composition has at least about 0.005 mg or more preferably 0.05 mg / g salsaponin per gram (or mg / g) of the extract or composition.

[0072] This indicates the lowest level of clematisin among the various blackcurrant juices tested by the inventors - see Example 4, although differences in the levels of bioactivity between different juices and other samples tested are noted. Through experience, the inventors have found that various factors such as high temperature processing (e.g. during pasteurisation), product time on shelf and storage conditions, fruit seasonality and plant variety can all have an impact on the levels of clematisin and its esters, and in some cases may even be negligible or absent.

[0073] Thus, it may be desirable or advantageous to concentrate, fortify, add or supplement clematisin in a composition or extract, or to select plants or fruits that advantageously have higher clematisin levels. Similarly, it may be advantageous to stabilize, protect, preserve, restore or further increase clematisin levels above those that naturally occur or have occurred in blackcurrant or its other source. Similarly, clematisin may ultimately be added to any substance for its intended use as described herein without departing from the scope of the invention.

[0074] In preferred embodiments, the extract or composition has at least about 0.005, 0.01, 0.02, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, or 17.0 g of extract or composition. 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0 or 200.0 mg of its clerodendron glycosides.

[0075] More preferably, the extract or composition has about 0.005-70.0 mg of salsaponin per gram (or mg / g) of extract or composition.

[0076] As further discussed in the preferred dosage section, a preferred minimum dose may be about 20 mg of clematisin per day. If blackcurrant juice has about 0.3 mg / ml of clematisin, an 86 mL serving size of the juice will achieve this minimum dose. One skilled in the art will appreciate that the concentration of clematisin may be appropriately adjusted in a desired extract or composition using conventional methods and practices to achieve an effective amount / dose and other criteria.

[0077] Similar embodiments are also envisioned for clematisin esters such as shown in Example 4. While the levels of the esters are low relative to clematisin, those skilled in the art will appreciate that there are means to increase the levels of these esters in an extract or composition if they are desired.

[0078] Sources of cyperus rotundus or its esters

[0079] Preferably, cyperoside can be extracted or isolated from a number of sources without limitation. In the past, cyperoside esters have been identified in blackcurrant seeds (Lu et al., 2002), and cyperoside has been identified in Kalanchoe species (Fernandes et al., 2021).

[0080] Here, the inventors have now surprisingly discovered clematisin and its esters in blackcurrant fruit and fruit extracts (such as dried extracts or juices). Therefore, preferably, clematisin is extracted or isolated from blackcurrant fruit. The extract may also contain other components from a source (such as blackcurrant) as this may provide additional benefits from biologically active substances or micronutrients. The inventors foresee that in alternative use embodiments, the whole fruit or plant material may be used to provide the beneficial MAO inhibition from clematisin or its esters, as long as the material does have this beneficial biological activity, which is the subject of this patent application.

[0081] Both CN102659860 and CN101974044B describe other methods for extracting clematis glycosides from other plant sources. These present alternative methods for extracting or isolating clematis glycosides for the novel uses of the present invention. While these may be suitable sources, it should be understood that other plants may also contain similar or higher levels of clematis glycosides or esters thereof that have been shown herein to have MAO inhibitory activity.

[0082] Alternatively, sources of clematisin or its esters may also be produced synthetically by known methods, either via microbial fermentation production from microorganisms that naturally express clematisin or via genetic modification using constructs encoding for recombinant expression of clematisin in standard cell culture methods.

[0083] Those skilled in the art will appreciate that, in addition to the currently discovered means, there are other means to achieve commercial production of clematis glycosides. This can be achieved by developing suitable plant varieties, which are genetically engineered, through cross breeding or multi-generation selection programs to produce new varieties with high levels of clematis glycosides or its esters. In other words, the present invention can be achieved by artificially producing clematis glycosides or its esters in high purity and providing, storing or selling them in purified form or suitably providing them in pharmaceutical compositions. This may be particularly useful for the pharmaceutical industry, which requires strict manufacturing requirements.

[0084] In the pharmaceutical embodiment, suitable forms include, but are not limited to, transdermal creams or patches, parenteral or subcutaneous injections, pills, capsules, etc. are all possible routes of administration.

[0085] Potential options for manufacturing methods

[0086] Juice from blackcurrants can be manufactured according to standard practice. For example, a juice concentrate can be obtained by evaporating the juice under vacuum to produce a concentrate having a concentration of approximately 10 times that of cassiabark.

[0087] The powder form of the juice can be produced by freeze drying or spray drying the juice. Therefore, those skilled in the art will appreciate that the present invention can be provided in various different dry forms such as capsules, tablets, powders, etc.

[0088] Pure clematisin can be obtained by chromatographically separating the juice or juice concentrate using reverse phase chromatography with multiple steps until pure clematisin is obtained.

[0089] Those skilled in the art will appreciate that there are also standard methods available for chemically synthesizing compounds such as cyperitoside or its esters. Such methods are encompassed within the present invention.

[0090] Likewise, cell expression systems are now routinely used to produce desired compounds on a large scale. For example, a natural or modified bacterial system can be selected or generated that overexpresses large amounts of clematisin, which can then be purified from cell culture.

[0091] Further examples of how compositions containing clethroidin can be prepared are in the Best Mode section of the specification.

[0092] Use and treatment methods

[0093] MAO inhibitors have shown promise and are associated with a range of diseases and conditions highlighted throughout this specification. Therefore, it is strongly expected that the now discovered scutellaria baicalensis or one of its identified esters having MAO inhibitory activity will most likely have new applications in both clinical and non-clinical treatment or prevention of these same or similar conditions. It should be understood that all MAO inhibitors generally share the same mechanism of action and are comparable in efficacy.

[0094] Preferably, the therapeutic use or method as described herein modulates, maintains or increases a neurotransmitter selected from the group consisting of dopamine, serotonin, adrenaline (norepinephrine or norepinephrine) and tyramine.

[0095] Potential clinical uses

[0096] Preferably, the therapeutic use or method as described herein is for treating or preventing a disease or condition in a human in need thereof, said disease or condition being any neurological or psychiatric condition or affliction associated with MAO-A or MAO-B enzyme activity.

[0097] Preferably, ophiopogon glycoside or its ester is used to treat or prevent depression, atypical depression, panic, social anxiety, bipolar disorder (especially depressive phase), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), adult ADHD, Alzheimer's disease, dementia, Parkinson's disease and / or Huntington's disease.

[0098] Non-clinical use

[0099] In addition, MAO inhibitors have shown potential applications for a range of non-clinical uses, as discussed throughout this specification. For example, Rhodiola, also known as golden root Rhodiala, contains MAO inhibitors and has been used to help mood, social anxiety, reduce fatigue and improve athletic performance.

[0100] Preferably, ophiopogon glycoside or its ester is used to improve, restore or support non-clinical effects such as mood, anxiety, social anxiety, fatigue, cognitive performance, motor performance, attention / alertness, calmness, mental clarity, executive function, working memory, secondary memory, mood, stress and / or stress reactivity, or to provide a nootropic effect.

[0101] Those skilled in the art will appreciate that other non-clinical uses related to cognitive and psychiatric support will also fall within the scope of the present invention and its uses.

[0102] Cnidium monnieri may also be mixed with other nootropics or bioactive substances known to benefit neurological status or prevent a condition or disease.

[0103] Preferred dosage

[0104] The inventors have conducted preliminary tests (see Example 5) to evaluate the possible effective dose of selegiline or its ester for clinical use, and may also provide guidance for non-clinical use. This is achieved by comparative enzyme inhibition analysis with a known commercial MAO-B inhibitor (depreniline) for clinical purposes. Extrapolation of the data from depreniline in Example 5 and the dosage guide (http: / / www.drugs.com / dosage / selegiline) suggests that the equivalent initial daily dose of selegiline for clinical use is 27.5 mg, and then after six weeks, if necessary, the daily dose can be increased to 65 mg.

[0105] Therefore, for clinical use similar to deprenil, the daily dose may preferably be at least 20 mg of scutellaria baicalensis or its ester.

[0106] More preferably, the daily dose is 20-200 mg of cleomeside or its ester.

[0107] More preferably, the daily dose is about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195 or 200 mg of clerodendron or its ester.

[0108] More preferably, the daily dose is 20 to 200 mg of cleomeside or its ester.

[0109] Another preferred daily dosage may be of the order of at least 110 mg / 60 kg body weight.

[0110] In a more preferred embodiment, the daily dose of cleometoside or its ester is 110-130 mg / 60 kg body weight.

[0111] In a nonclinical setting, the preferred dosage may be significantly less than in a clinical setting.

[0112] Preferably, for non-clinical uses (e.g., for preventive, supportive or maintenance effects on mood or cognition - as discussed above), the serving size / daily serving may be as low as 1 mg-20 mg, although higher doses similar to the preferred clinical doses may also be useful and are within the scope of the invention.

[0113] Key advantages of the present invention

[0114] The present invention may include but is not limited to one or more of the following advantages:

[0115] - Identification of novel uses of ophiopogonis glycosides and their esters as MAO inhibitors with potentially significant opportunities for therapeutic and non-clinical uses.

[0116] - Various embodiments of the present invention may beneficially utilize naturally occurring sources of salvia aviculare or its esters due to the fact that it is present in several plant materials, including black currant.

[0117] -Preliminary evidence suggests that cypermethrin has minimal or no adverse side effects.

[0118] - Preliminary evidence suggests that ophiopogonis glycosides advantageously possess inhibitory activity against both MAO-A and MAO-B, opening up additional uses.

[0119] -Preliminary evidence suggests that cyperitoside favorably and reversibly inhibits MAO-A and MAO-B. BRIEF DESCRIPTION OF THE DRAWINGS

[0120] Further aspects of the invention will become apparent from the ensuing description, given by way of example only, and with reference to the accompanying drawings.

[0121] Figure 1 Referring to Example 1, βC from blackcurrant juice is reported. Compound 1 (LHS) and Compound 2 (RHS).

[0122] Figure 2 Reference Example 1, a third βC (Compound 3) found in blackcurrant.

[0123] Figure 3 Referring to Example 1, LCMS analysis of blackcurrant juice was tested.

[0124] Figure 4 Reference Example 1, Neuroberry TM Chromatograms of juice samples 1, 2, and 3 (from top to bottom).

[0125] Figure 5 Referring to Example 3, the levels of 4HQ observed in the fractions (lower values ​​indicate greater inhibition)

[0126] Figure 6 Reference Example 3, Preparative HPLC trace (UV). Fractions 18-23 were collected from 7-11 minutes.

[0127] Figure 7 Referring to Example 3, levels of 4HQ observed in fractions from large-scale preparative hplc (lower values ​​indicate greater inhibition)

[0128] Figure 8 Referring to Example 3, the chemical structure of cyperus rotundus is shown.

[0129] Fig. 9 Referring to Example 3, the chemical structure of the nigromatine compound is shown.

[0130] Fig.10 Referring to Example 3, the activities of fractions 17-22 from preparative HPLC relative to the cyperoside content.

[0131] Fig.11 Refer to Example 3, H NMR spectrum of the preparative HPLC fraction.

[0132] Fig.12 Refer to Example 3, H NMR spectrum, details of the 5-10 ppm region.

[0133] Fig.13 Reference Example 3, levels of 4HQ in bioassays of reverse phase fractions rp-1 to 11.

[0134] Fig.14 Reference Example 4, RP10 fraction 4HQ (S9 bioactivity from preparative HPLC fractions of RP10)

[0135] Fig.15 Referring to Example 4, coumaroyl and feruloyl pyralidin contents in RP10 HPLC fractions (fractions 12-15 have higher peak areas than shown).

[0136] Fig.16 Reference Example 4, Caffeoyl cynaroside Peak Area Content in RP10 HPLC Fraction

[0137] Figure 17 refers to Example 5, A) Dilution series of cyperoside. 50% inhibition occurs at about 400 ng / ml. B) Dilution series of depreniol. 50% inhibition occurs at about 10-15 ng / ml.

[0138] Fig.18 Referring to Example 6, a graph showing the concentration of clethrin in the samples relative to the concentration of each sample required for 70% inhibition of MAO-b.

[0139] Fig.19 Refer to Example 7 for a flow chart of the progression through the stages of a randomized crossover trial with two model groups.

[0140] Fig. 20 Refer to Example 7 for the procedures performed on the 1st and 2nd test days of the intervention study.

[0141] Fig.21Concentrations of total anthocyanins (A), cyanidin derivatives (B, C, D) and delphinidin derivatives (E, F) in plasma before (0 min) and after consumption of black currant beverage intervention (mean ± SEM) with reference to Example 7. Data are presented as cyanidin 3-O-glucoside equivalents.

[0142] Fig. 22 Referring to Example 7, salvia aviculare concentrations in plasma before (0 min) and after consumption of a single dose of blackcurrant juice or powder (mean ± SEM).

[0143] Fig.23 Referring to Example 7, platelet monoamine oxidase (MAO)-B activity and blood glucose concentration before (0 min) and after consuming blackcurrant juice (A, C) or powder (B, D) and their corresponding placebos. Values ​​are mean ± SEM. * indicates a significant difference from 0 min (p < 0.05). ^ indicates a significant difference from the placebo intervention at the same time point.

[0144] Fig.24 Referring to Example 7, the visual analog ratings of the Bond-Lader questionnaire items of interest / boredom (A, B), friendliness / unfriendliness (C, D), happiness / sadness (E, F) and calmness / excitement (G, H) given by participants before (0 min) and after consuming blackcurrant juice or powder and their corresponding placebos. Values ​​are mean ± SE. *Indicates a significant difference from the placebo intervention at the same time point.

[0145] Fig.25 Referring to Example 7, Spearman rank sum correlation coefficients of neurotransmitters showing significant correlations (*p<0.05, **p<0.01) with MAO-B inhibition after consumption of blackcurrant juice intervention versus placebo or blackcurrant powder intervention versus placebo.

[0146] FIG26 shows the difference in concentrations of circulating plasma neurotransmitters (Δng / mL) (mean ± SEM) between time points (t) = 0 and t = 10, 20, 120, 240 and 480 min after consuming black currant juice intervention versus placebo or black currant powder intervention versus placebo, with reference to Example 7. (A) 3,4-dihydroxyphenylacetic acid (DOPAC) juice intervention, (B) DOPAC powder intervention, (C) homovanillic acid (HVA) juice intervention, (D) HVA powder intervention, (E) vanillylmandelic acid (VMA) juice intervention, (F) VMA powder intervention, (G) dopamine (DA) juice intervention and (H) DA powder intervention.

[0147] Fig. 27Referring to Example 7, the concentration differences (Δng / mL) of circulating plasma neurotransmitters between time points (t) = 0 and t = 10, 20, 120, 240 and 480 min after consuming black currant juice interventions versus placebo or black currant powder interventions versus placebo (mean ± SEM). (A) 5-hydroxyindoleacetic acid (5-HIAA) juice interventions, and (B) 5-HIAA powder interventions. * indicates a significant difference (p < 0.05) between the intervention and the placebo at the same time point.

[0148] Fig.28 Referring to Example 7, the difference in concentrations (Δng / mL) of circulating plasma neurotransmitters between time point (t) = 0 and t = 10, 20, 120, 240 and 480 min after consumption of black currant powder intervention versus placebo (mean ± SEM). (A) xanthurenic acid (XA), (B) metanephrine (MN), (C) normetanephrine (NM) and (D) kynurenic acid (KA).

[0149] Fig.29 Referring to Example 7, the concentration difference (Δng / mL) of circulating plasma neurotransmitters between time points (t) = 0 and t = 10, 20, 120, 240 and 480 min after consuming black currant juice intervention versus placebo or black currant powder intervention versus placebo (mean ± SEM). (A) 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) juice intervention, (B) MHPG powder intervention, (C) 3,4-dihydroxyphenylethylene glycol (DHPG) juice intervention, (D) DHPG powder intervention, (E) phenylalanine (PHE) juice intervention and (F) PHE powder intervention. * indicates a significant difference (p < 0.05) between the intervention and placebo at the same time point.

[0150] Fig.30 Reference Example 7, blackcurrant (A) and placebo (B) beverages (combination of juice and powder) standardized neurotransmitter concentrations as dependent variables pie chart. Only the 12 variables with the strongest contribution to the definition of the main component are shown. Variables with warm and cool colors have higher and lower weights, respectively. The coordinates of the variables correspond to their correlation coefficient values, and the angle between the two variables defines their relationship: if the angle between the two variables is an acute angle, the correlation is positive; if the angle is an obtuse angle, the correlation is negative; if the angle is a right angle, the correlation is zero. DETAILED DESCRIPTION

[0151] Example 1 - Overview of previous developments and preliminary studies on β-carbolines

[0152] Overview

[0153] Previous studies have indicated that consumption of black currant (BC) juice affects the monoamine axis in human subjects. In 1994, Budzikiewicz demonstrated that BC contains two β-carbolines (βC) - see Figure 1 . This class of compounds is known to interact with MAO. As mentioned previously, in 2006 and 2018, Herraiz et al. demonstrated that a variety of juices and fruits, including BC, contain beta carbolines (βC). When they compared a range of βCs, they found potent MAO activity in some of the βCs. MAO-B activity was shown to be inhibited by consumption of BC juices. The activity was thought to be reversible and non-selective, but may have a greater affinity for MAO-B. These βC compounds were present in the juices at very low levels, but the inventors considered βC to be an obvious candidate for MAO inhibitory activity in BC juices.

[0154] Embodiment 1 includes:

[0155] · Develop an analytical method to detect low levels of β-carbolines in BC samples. This would involve processing large quantities of BC juice or frozen berries (10 kg) to specifically extract βC.

[0156] Prepare samples with enhanced βC using buffered reactions of common precursors

[0157] · Detection of βC in juice and fortified samples using LC-MS and LC-HRMS

[0158] Methods and results of analyzing βC in BC.

[0159] The analysis of these βCs is most conveniently performed using LCMS. Alkaloids tend to ionize well in mass spectra, and specific MRM analysis allows for more accurate analysis in complex mixtures. Initially, juice samples were extracted with ether, which produced an ether extract enriched in βC. These extracts were then subjected to LCMS, and peaks corresponding to the masses of the two known βCs were identified (279 and 323 (MH+) for 1 and 2).

[0160] During this work we also noted the presence of another βC with MH+ of 231, which was identified as methyltetrahydro-β-carboline (see Figure 2 ).

[0161] Compound 1-3 (in Figure 1-2 The laboratory reaction of tryptophan with aldehydes to produce compounds of this type is called the Pictet-Spengler reaction. Even under fairly mild conditions, such as those found in fruit juice, tryptophan will react with aldehydes to produce these products.

[0162] To assist in compound identification and samples required for activity testing, two compounds can be prepared. Compound 1 is prepared from ascorbic acid and tryptophan, while compound 3 is prepared from tryptophan and acetaldehyde. The ascorbic acid reaction may involve an initial conversion of ascorbic acid to the aldehyde and has a low yield. The reaction with acetaldehyde proceeds more rapidly. Compound 2 can be formed from hydroxymethylfurfural (HMF), but then requires a further methylation step.

[0163] The preparation of compounds 1 and 3 was performed on a small scale and provided sufficient material to confirm that the synthetic compounds matched the natural compounds and also to optimize the MS analysis in LCMS. The prepared compounds were also prepared and used in Example 2.

[0164] Figure 3 The chromatogram of the test drink sample containing BC is shown. Only the three channels of βC are shown, the blue trace is compound 3, while the peak at about 17 min is compound 1, and the weaker peak at about 13 min is compound 2. We cannot quantify these compounds, but it is clear that compound 3 shows a strong reaction in this analysis.

[0165] Using this approach, we can then examine other relevant samples. TM Blackcurrant samples were used for analysis. Juice from several berries of each was also squeezed out, centrifuged and analyzed after dilution 1:1 with water. Neuroberry TM The chromatograms of the samples are shown in Figure 4. This shows that the amount of βC in the three berry juice samples varies to a considerable degree. For example, compound 3 has peak areas of 3.8, 9.0 and 4.9 (relative peak area in millions).

[0166] Samples of frozen BC juice concentrate and dried BC extract powder were also analyzed. BC powder is a dried ethanol extract of BC. Both the dried ethanol concentrate and the frozen juice concentrate contained the three βCs identified above.

[0167] Comparison of fresh juice and dried extract

[0168] As mentioned above, both fresh juice and dried alcoholic extracts contain βC. However, there are clear differences between juice and alcoholic concentrates. The most obvious is the lack of polar components in the ethanol extract. This is expected because polar compounds such as sugars and food acids are less soluble in ethanol. Two compounds of particular interest in this work are ascorbic acid and tryptophan. Tryptophan is a precursor to the βC discussed above, and βC is known to form in juice, and most likely during juice processing. Ascorbic acid is also important in this case because some βC is formed by the reaction of ascorbic acid with tryptophan.

[0169] Analysis of the dried ethanol extract showed the absence of ascorbic acid, and moderate levels of tryptophan. High levels of ascorbic acid and tryptophan were observed in both juice and juice concentrate. The actual levels of these components have not yet been determined.

[0170] Overview

[0171] We have developed a method to screen blackcurrant juice products for low levels of specific β-carbolines. Three compounds were identified in fresh juice, juice concentrate, and dried ethanol extract.

[0172] Two beta-carbolines have been identified that are produced from tryptophan in combination with ascorbic acid or acetaldehyde. These types of compounds have been shown to form during the processing of juices and some fruits.

[0173] The ethanol extract of blackcurrant shows the absence of ascorbic acid. The absence of ascorbic acid and other polar compounds may reduce the formation of β-carbolines in vivo.

[0174] The inventors reasoned that a more detailed analysis might be needed to determine in vitro MAO activity in βC-enriched juices and samples.

[0175] Example 2 - Bioassay

[0176] In previous Example 1, we identified some βC in BC samples, and we also prepared some βC-enhanced samples in preparation for use in our bioassays.

[0177] Most commercial MAO assay kits work by measuring hydrogen peroxide formation (produced when MAO deaminates monoamine substrates). This method can be interfered with when antioxidants are present in the sample (antioxidants can inhibit peroxide formation). Work by Herraiz et al. (2018) demonstrated that alternative direct analysis of deaminated substrates using HPLC is a viable option. Using this approach, they demonstrated that common food phenolic compounds such as quercetin and cyanidin were not active (instead, they inhibited the peroxidase used in the commercial assay).

[0178] In Example 2, the inventors:

[0179] Testing for MAO-B and possibly MAO-A inhibition using in vitro assays utilizing commercial kits;

[0180] • An HPLC assay was used to confirm activity in various samples including BC juice, dried ethanol extract (35% anthocyanins) and the test βC produced in Example 1.

[0181] Methods and Results

[0182] In this example, we focused on evaluating the effects of BC juice in vitro using a commercial kit-based MAO assay.

[0183] For MAO-A and MAO-B enzymes, the kits used were from Sigma-Aldrich [MAK295 / 296]. The kit method detects peroxide formation (caused by MAO activity) via the production of a fluorescent product. Since BC samples are complex mixtures containing some fluorescent components and a high color background, only a limited number of samples can be assayed per kit (due to the need for multiple control and background samples).

[0184] In the first kit assay run, we investigated samples of freshly extracted blackcurrant juice, dry extract, a test drink containing blackcurrant juice (aged) and a mixture of the two β-carboline samples prepared in Example 1 (compounds 1 and 3).

[0185] The results are shown in Table 1 below. The values ​​in mg / ml in the table are approximate values ​​for the juice content based on anthocyanin comparison. This was determined by measuring the anthocyanin concentration of the dry extract and juice concentrate (UV-Vis) relative to the fresh juice. Thus, the juice concentrate was 4.5 times the concentration of the juice and the dry extract was 73 times the concentration of the juice. The test beverage was known to be a 1:1 dilution of the juice.

[0186] Table 1. Results from the first round of assays

[0187]

[0188] These results are very encouraging. We observed good MAO-A and MAO-B inhibition for both the pure juice samples and the juice concentrates. We also observed inhibition for both the dry extracts and the test drink products.

[0189] However, we observed little inhibition for the β-carboline mixture. While this latter result is somewhat disappointing, it is only two from a range of possible βCs, and published work has shown great variation in βC activity depending on structure.

[0190] Overall, both MAO-A and MAO-B inhibition was observed in the active samples, with the best rates tested at approximately 10 mg / ml juice equivalents.

[0191] A second round of kit testing was performed (Table 2 below). For this round, the juice was retested at three dilutions (i.e., 20, 10, and 5 mg / ml). These samples showed consistent MAO-A results with the previous set, with good on-scale activity at 5 and 10 mg / ml juice equivalents.

[0192] Due to the continued interest in activities consistent with flavonoid / anthocyanin polyphenols in the juice, we also tested a series of fractions that attempted to separate polyphenols and activities, and the results are shown in Table 2.

[0193] Extracts E1, E2 and E3 are samples prepared by ether extraction of juice concentrate (diluted in water). E2 is the ether extract of E1 after alkalization, and E3 is the ethyl acetate extract of E2.

[0194] None of these extracts were active, indicating that the activity was not related to the non-polar portion of the extracts and was therefore unlikely to be associated with known β-carbolines.

[0195] Another way to separate the polyphenols from the "other" components is to pass the extract through a polyamide column. The results are also shown below in Table 2. In this case, a small sample of the juice (from the concentrate) was prepared in 0.25% acetic acid and loaded onto the polyamide column, PA1 was the loading fraction, PA2 was the polar non-phenolic fraction eluted with 0.25% acetic acid, PA3 was the main polyphenol fraction (colored) eluted with 1:1 methanol:water, and PA4 was eluted with pure methanol. The most activity was observed in fraction PA2, which was the polar material separated from the main anthocyanin / polyphenol fraction (PA3). This tells us that the main activity is surprisingly not related to anthocyanins / polyphenols, as expected, and is not related to β-carbolines.

[0196] Table 2. Results from the second round of assays.

[0197]

[0198]

[0199] In this second round of assays, the MAO-A results were generally on scale, whereas MAO-B appeared to be more sensitive, with most results > 100%. However, we still observed MAO-B activity that was consistent with MAO-A, indicating that we only needed to perform one assay to follow up on activity in subsequent examples.

[0200] Overview

[0201] Activity testing using Sigma-Aldrich commercial kits has shown consistent MAO-A and MAO-B activity for juice, juice concentrate, and dried juice extract. The activity is concentration dependent. MAO-A and MAO-B activities appear to track together, so for efficiency, only one (MAO-A) assay is recommended for future examples.

[0202] Testing of some fractions to separate polar and non-polar components from the main juice polyphenols showed that the activity was associated with the polar non-polyphenolic fractions from the juice. This suggests that the activity is not due to the known β-carbolines, as they would be concentrated in the non-polar fractions. This work led to Example 3, the purpose of which was to identify the specific fractions and components responsible for the MAO inhibitor activity.

[0203] Example 3: Bioassay-guided fractionation

[0204] Overview

[0205] In Example 3, the inventors investigated fractionation methods in an attempt to narrow the identity of the active component.

[0206] Methods and results.

[0207] To allow screening of a larger number of fractions / samples, an alternative assay to the Sigma-Aldrich commercial assay kit used in Example 2 was used in Example 3. We used porcine S9 liver microsomal fractions as a source of MAO-A and MAO-B enzymes. This approach allowed screening of many more samples than possible with a kit-based assay. S9 porcine liver microsomes were isolated from macerated porcine liver.

[0208] The S9 porcine fraction was mixed with a specific MAO substrate (kynurenine) and mixed with the test sample and buffer. After 1 hr at 37°C, the reaction was stopped by cooling and adding 2N NaOH and acetonitrile. The centrifuged samples were then analyzed using LCMS and the level of 4-quinolol (4HQ) product was measured.

[0209] The method was performed according to the protocol described in Ghosal (2020) (entitled "Evaluation of the clearance mechanism of non-CYP-mediated drugmetabolism and DDI as a pancrim drug"). The method utilizes the spontaneous formation of 4-quinolol from oxidized kynuramine. The levels of kynuramine and 4-quinolol were assessed by LCMS, and low levels / absence of 4-hydroxyquinolol indicated inhibition of MAO.

[0210] This method proved to be very useful for following MAO inhibitory activity through many separation steps.

[0211] Primary separation was performed using column chromatography (CC).

[0212] Use three CC modes.

[0213] 1. Reverse Phase Chromatography (RP CC)

[0214] Initially, a small scale column was run with a micro RP column, eluting with water and then with increasing proportions of methanol.

[0215] MAO inhibitory activity was observed only in the most polar fractions (ie, those eluting at the beginning).

[0216] Thereafter, a larger sample of the juice concentrate (5 g) was dissolved in water and the pH was adjusted to pH 5.5 with 2N NaOH. The extract was applied to a larger C18 silica RP column and eluted with water (two fractions), followed by acidified water (2 fractions), followed by 15% ethanol in water and finally ethanol.

[0217] Assays of these larger fractions showed that the major activity was confined to the two initial water fractions.

[0218] 2. Cation Exchange Chromatography

[0219] Small scale chromatography using commercial preformed columns (SPE type). Juice concentrate samples were dissolved in pH 8 buffer and loaded onto the column. The column was then rinsed with 0.1 N HCl, followed by water and then NaOH.

[0220] The MAO inhibitory activity was concentrated in the loaded fraction, ie, not retained on the column.

[0221] 3. Anion Exchange Chromatography

[0222] Several trials were performed using anion exchange material. Initially, it appeared that the activity was retained on the column and eluted with acid. However, the assay proved to be somewhat sensitive to trace amounts of acid, so that when the sample was completely dried and reconstituted in water, the activity was limited to the loaded fraction.

[0223] These results confirm that the active material in the BC juice concentrate is polar (eluting early on the RP CC) and is neither acidic nor basic in nature (not retained on anion or cation exchange media).

[0224] Preparative HPLC

[0225] Preparative HPLC was the next step to further narrow down the activity. First, a chromatographic run was performed using a 250×10 mm Luna C18 column. Fractions were collected every minute and a gradient of acetonitrile in acidified water was used. A subsample of each fraction was taken and dried before assay. The assay spectrum is shown in Figure 5 As shown, the activity was confined to the early fractions in the HPLC run, primarily in fractions 3 and 4, but also in 8.

[0226] To further narrow down the activity, a second preparative HPLC run was performed (see Figure 6 This used a larger column (Supelco Ascentis C18, 250 x 22 mm) and collected more fractions around the region of interest (fractions 18-23 at 7-11 min).

[0227] like Figure 7 As shown in , the most active fractions in the assay were 19 and 20. LCMS analysis indicated that these fractions were likely a single compound with a molecular weight of 276. High resolution MS indicated formula C 11 H 17 O7N. The major ion seen in negative mode was the formic acid adduct (m / z 320). Fractions 19 and 20 were combined and an NMR spectrum was obtained. The NMR data indicated the presence of a sugar (probably glucose). A literature search using the identified formula and the presence of the sugar enabled the most likely candidate to be identified as cyperidin (e.g. Figure 8 ), a nitrile glycoside previously isolated from plants such as Kalanchoe species. Comparison of the NMR data with that of scutellaria serrata confirmed this assignment.

[0228] To the best of the inventors' knowledge, there has never been any identification or discovery of MAO activity from clematis glycosides. Thus, the present invention relates to novel uses of clematis glycosides derived from natural sources (e.g., analogs that may be derived from blackcurrant or Kalanchoe species) or otherwise (such as by cell-based fermentation and purification techniques or synthetic production of the compound) as MAO inhibitors (and related uses thereof, as described elsewhere in this specification).

[0229] Prunosin can be classified as a gamma-hydroxynitrile glycoside. This is an unusual class of hydroxynitrile glycosides, as most known hydroxynitrile glycosides are alpha-hydroxynitrile glycosides (e.g., prunasin from apple seeds).

[0230] like Fig.10 As shown in , further HPLC analysis of the most active fraction group appears to show the highest levels of clematisin in fractions 18 to 21. This appears consistent with clematisin being the active component.

[0231] We also carefully examined the NMR spectra of the fraction immediately preceding and of the fraction containing scutellarin (see Fig.11 ). Combined fractions 19 and 20 showed the main NMR signal of clematisin and only small amounts of other compounds. Fraction 18 was similar, with a few small peaks in the 5.5-9 ppm region. Fraction 17 had a small amount of clematisin, while the other peaks in the 5.5-9 ppm region were larger (see Fig.12Fraction 16 (inactive) had no cyperoside and also lacked other signals in the 5.5-9 ppm region.

[0232] This is consistent with cleometoside being the source of activity in these fractions.

[0233] Review the column chromatography fractions again.

[0234] In the case of identifying possible activity in the polar fractions, we decided to examine the fractions from the reverse phase C18 column for any additional activity. A fresh column was run using 5 g of concentrate and 11 fractions were collected. When these fractions were assayed using the S9-LCMS method, a second active band was observed in the late eluting non-polar fraction (see Fig.13 ). Fraction 10 was active. The major cyperoside fraction was fraction 2.

[0235] Analysis of fraction 10 revealed the presence of a group of flavonol glycosides as well as some other phenols. Among these phenolic compounds, we identified Fig. 9 The presence of two nigromatine ester derivatives of scutellaria serrata is shown. These two related compounds, although again not identified as having MAO inhibitory activity, have been previously isolated from blackcurrant seeds (Lu et al., 2002). These are nigromatine-p-coumarate and nigromatine ferulate ( Fig. 9 ). They are phenolic acid derivatives of cyperus rotundus.

[0236] A sample of fraction 10 was subjected to RP preparative HPLC and the fractions were assayed using the S9 assay as used previously. The results (shown in Figure x) indicated three active bands, namely fractions 9 / 10, fractions 12-16 and a late band (fraction 21).

[0237] These active fractions were analyzed using LCMS (as above). Coumaroyl and feruloyl groups appear to be concentrated in fractions 12 to 16 (Figure x, peak areas relative to fraction number). This is consistent with the activity shown in the fraction bands. Fractions 9 and 10 shown also show some characteristic mass spectrometry peaks to indicate the presence of additional cypermethrin esters. This was determined to be the caffeoyl ester of cypermethrin with a characteristic MRM transition (m / z 436->179). This appears to be the compound responsible for the activity observed in fractions 9 and 10 (Figure x).

[0238] Note that the HPLC fractions are primarily mixtures of compounds. In many of these fractions, but especially fractions 8-12, high levels of other components, primarily flavonoids, are present.

[0239] Fractions 13 and 14 were mainly composed of ester compounds.

[0240] By obtaining purified samples of the two nigrolumine esters from historical work and performing the S9-LCMS assay, the nigrolumine mixture had about the same activity level as scutellarin. This strongly supports that the active compound in the S9 assay is scutellarin. Scutellarin esters (nigrolumine ferulate / coumarate) are likely hydrolyzed by the S9 enzyme to produce scutellarin.

[0241] Extract comparison

[0242] In human studies, the ethanol extract powder (DelCyan) was less effective in altering MAO activity. In this work, the inventors analyzed the provided blackcurrant powder and found only very low levels of cyperoside (compared to juice or juice concentrate). This was also evident in the S9 LCMS bioassay, where the juice concentrate was more active than the dry extract when compared at the same level of total anthocyanins (dry extract 73× juice, concentrate 4.5× juice). It is expected that the dried extract will still contain nigromatine esters.

[0243] Overview

[0244] In summary:

[0245] • MAO inhibitory activity appears to be traced primarily to cyperidin and to a lesser extent to cyperidin esters.

[0246] • Activity was most easily observed using the crude liver S9 fraction containing the enzyme cocktail.

[0247] Example 4: Further analysis of the activity of scutellaria baicalensis in samples

[0248] Overview

[0249] In Example 4, samples of active compounds were purified from juice concentrates (scaled up from Example 3) to give about 10 mg of each active compound. In addition, juice or other berry samples (e.g. blueberry and various blackcurrant samples) were analyzed for their content of these active substances. Finally, the ester-containing fractions were fractionated and bioassayed (S9 assay) to confirm the activity of the esters.

[0250] result

[0251] 1. Purification of active compounds.

[0252] Approximately 2 kg of frozen berries were blended with an equal volume of 1:1 ethanol:water. A fine nylon cloth was used as a filter to separate the liquid from the residual solids. The ethanol was removed from the filtrate by rotary evaporation. Half of the liquid extract was then applied to a reverse phase chromatography plug (dimensions of 9 cm diameter and 4 cm deep). After loading, the column was eluted with water containing 0.1% formic acid and with increasing proportions of ethanol in water.

[0253] The fractions were analyzed using LCMS. Ceratidine was concentrated in the fractions eluted with water and up to 5% ethanol, whereas ceratidine ester was found in the fractions eluted with 40% to 60% ethanol.

[0254] The remaining extracts were chromatographed in a second run.

[0255] The fractions containing clematisin were combined, freeze-dried and rechromatographed using the same column. The clematisin-rich fractions from this separation were then used for preparative HPLC. Preparative HPLC was performed using a Gilson preparative system, eluting with acetonitrile and 0.1% formic acid in water, using a gradient starting with 1% acetonitrile and ending with 15% acetonitrile. The purity of the clematisin fractions was assessed using LCMS and 1H NMR.

[0256] Similarly, the scutellariae-enriched fractions were combined, re-chromatographed using a RP plug, and finally purified using preparative HPLC (same system as above, but using a modified gradient, 5% to 40% acetonitrile). The purity of the esters was assessed using LCMS.

[0257] 2. Sample analysis.

[0258] Four comparative blackcurrant juice drinks which we have labeled as samples 1-4 were used and compared with the applicant's test blackcurrant juice sample which was taken as pure Neuroberry TM Black currant juice extract (Sample 5) and provided as concentrated juice (Sample 6) and in commercial form (Sample 7).

[0259] In addition, we tested two extracts from freeze-dried blackcurrant (Samples 8 and 9), which were a useful comparison to the applicant's tested dried extract containing blackcurrant material (Sample 10).

[0260] The samples were analyzed using LCMS. Standards were prepared for cyperoside, feruloyl cyperoside, and coumaroyl cyperoside. The analysis used the specific mass data (MRM) for each analyte and the peak areas of the samples were compared to those of the standards.

[0261] The juice was analyzed neat or diluted 1:1. Freeze-dried berries were extracted with water or ethanol:water (1:1).

[0262] These values ​​were then compared to those obtained for samples 5-7.

[0263] The results are shown in Table 3. Note that the clematisin content is shown in mg / g sample, while the esters are in μg / g. From this data we can see that sample 5 has about 15 times more clematisin than each ester. The amounts of both esters are similar.

[0264] Based on these initial results, the inventors believe that typical clematisin levels in different types of blackcurrant juices / extracts may generally range from about 5 μg / g to 1300 μg / g. Therefore, in one aspect of the invention, the inventors foresee the use of juice extracts or other forms having clematisin or esters within this range for new uses for MAO inhibition, or advantageously increased above this level to increase the potency or effectiveness of the composition, nutraceutical or extract.

[0265] We can also infer that freeze-dried berry extract samples 8 and 9 had roughly the same content as sample 5. Juice sample 2 was roughly similar to sample 5, although the level of clematisin was slightly lower. In juice sample 4, the clematisin content was consistent with the juice content of 5.7%. Test drink product 7 was from an aged sample stored at room temperature, so it is possible that some clematisin was lost over time. The test drink was a 1:1 dilution of juice, so it is expected to contain about 0.7-0.8 mg / g clematisin typically in fresher samples. Both the concentrated beverage sample 6 and the dry powder (sample 5) were very high in clematisin compounds, however the dry extract had proportionally lower levels of clematisin (esters were about three times the level in sample 6, but clematisin was lower). This may be a function of the use of ethanol, which will favor the extraction of less polar esters.

[0266] Table 3. Analysis of the contents of cassia glycosides and esters in various blackcurrant juice products.

[0267]

[0268] Fractionation and bioassay of ester-rich fractions

[0269] In Example 3, it was noted that a less polar fraction from reverse phase chromatography was also active in the S9 bioassay. This fraction (RP10) showed good activity and appeared to contain the scutellaria serrata esters discussed above.

[0270] A sample of RP 10 was subjected to RP preparative HPLC and fractions were determined using the S9 assay as previously used. Results ( Fig.14 ) indicated three active bands, namely fraction 9 / 10, fractions 12-16 and a late band (fraction 21).

[0271] The active fractions were analyzed using LCMS (as above). Coumaroyl and feruloyl groups appeared to be concentrated in fractions 12 to 16 ( Fig.15, peak areas relative to fraction number). This is consistent with the activity shown in the fraction bands. Fractions 9 and 10 shown also show some characteristic mass spectrometry peaks to indicate the presence of additional clematisin esters. This was identified as the caffeoyl ester of clematisin with a characteristic MRM transition (m / z 436->179). This appears to be the compound responsible for the activity observed in fractions 9 and 10 ( Fig.16 ).

[0272] Note that the HPLC fractions are primarily mixtures of compounds. In many of these fractions, but especially fractions 8-12, there are high levels of other components, primarily flavonoids. Fractions 13 and 14 are dominated by ester compounds. The later active fraction (22) does not show any peaks in the LCMS to distinguish it from fractions 20 or 22.

[0273] in conclusion

[0274] This study on blackcurrant juice has demonstrated that clematisin is present at relatively high levels in the juice samples. Phenolic esters of clematisin are also present at low levels and are also active. Coumaroyl and feruloyl esters are the main esters, but caffeoyl esters have also been identified in the active fractions.

[0275] Example 5: Comparison of MAO-B activity of cyperidin relative to deprenil

[0276] Overview

[0277] This example compares the MAO-B activity of selegiline (also known as depregnir or L-depregnir and sold under brand names such as Eldepryl and Emsam, a known MAO-B inhibitor and used to treat Parkinson's disease and major depressive disorder). This helps to verify the effective dose of selegiline alone or, for example, in an extract such as juice.

[0278] result

[0279] Deprenil was purchased from Sigma-Aldrich. (R-(-)-Deprenil, the compound also known as selegiline). The sample of selegiline was from material purified in earlier work. The concentration of selegiline was confirmed using NMR with quantitative NMR standards. The S9 liver microsomal fraction containing the crude enzyme mixture was from a frozen bulk sample derived from pig liver.

[0280] Samples were prepared in a 6-well plate (deep well format with 1.1 mL strip tubes). The assay was performed by diluting the crude S9 fraction with buffer (PBS, pH 7.4, 1:5 dilution, 150 μL) and adding the test sample dissolved in buffer (75 μL). An aliquot of kynurenamine (10 μL, 1 mg / ml) was added and the plate was placed in a 37°C water bath for 1 hr. The plate was cooled in ice water and then 20 μL of 2N NaOH was added followed by 250 μL of acetonitrile. The individual strip tubes were centrifuged and samples were taken from each strip tube for LCMS analysis.

[0281] LCMS analysis was performed using a Cyano HPLC column (eluted with 0.1% formic acid in water and acetonitrile). The LC run was in isocratic mode (40% acetonitrile) and the relative levels of 4-hydroxyquinoline (4HQ) and kynurenine were determined from the peak areas. The inhibition % was determined by comparing the amount of 4HQ to the amount of the buffer only sample well. Kynurenine is converted to 4HQ by the MAO-B enzyme.

[0282] The results of this analysis are described below with reference to FIG. 17 .

[0283] - 50% inhibition of scutellaria baicalensis was observed at approximately 400 ng / ml (equivalent to a concentration of 1.45 μM).

[0284] - 50% inhibition of Depresnil was observed at approximately 15 ng / ml or 67 nM.

[0285] - This indicates that depresnil is a 22-fold more potent MAO-B inhibitor than cypermethrin.

[0286] -The recommended minimum starting dose of depresnil (selegiline) is 1.25 mg / day and is increased to 2.5 mg / day after 6 weeks (see https: / / www.drugs.com / dosage / selegiline.html).

[0287] discuss:

[0288] Based on these results, a preferred dosage of clematisin for MAO-B inhibition for cognitive diseases or prevention / improvement of mental health is at least about 27500 μg clematisin / day.

[0289] Thus, for a black currant juice comprising, for example, 320 μg / g clematisin, a daily serving of 86 mL of such black currant juice would provide approximately 27,500 μg clematisin, which would provide a particularly preferred effective dose when used to achieve MAO-B inhibition (i.e., would be equivalent to an effective dose of 1.25 mg depresnir when a 22-fold conversion is applied).

[0290] Example 6: Analysis of cassiabarbital content / MAO activity in a range of blackcurrant berries, juices and juice concentrates

[0291] Overview

[0292] This example evaluates a range of blackcurrant cultivars for both MAO activity (S9 assay as above) and calendulaside content (LCMS analysis).

[0293] result

[0294] As part of the ongoing improvement of analytical methods, the LCMS method used for previous work was adjusted. The previous method had issues with overlapping metabolites eluting at approximately the same time as clematisin. This resulted in interactions between the metabolites, producing suppression of the clematisin signal and therefore incorrect concentration estimates. The HPLC method was improved by using 10 mM ammonium formate in aqueous solvent (instead of 0.1% formic acid). This change shifted the clematisin peak to elute later than the edible acids and sugars and gave more consistent results for samples and standards.

[0295] As part of this work, the clematisin standard was also re-evaluated. Previously, the standard was a sample of clematisin isolated by preparative HPLC and certified as "pure" using NMR.

[0296] However, when the purity was assessed using a quantitative NMR standard, the sample was found to have a lower purity. All subsequent analyses were based on this new NMR standard.

[0297] Various juice samples, concentrates, powders and whole fruit were tested. Each sample was diluted with water to give a clematisin peak around the appropriate concentration for LCMS analysis. From the results from Example 5, we can estimate the approximate concentration of clematisin required to produce 20-80% inhibition in the S9 assay. Samples for the assay were diluted to this approximate concentration by dilution with water and the assay was performed in a 2-fold dilution series using 4 wells for each sample. Due to reagent supply limitations, only one assay was performed on each sample.

[0298] The results are shown in Table 4 below, where there is the amount of clethrin in each sample, followed by the sample concentration (mg / g) that produced 70% or 80% inhibition in the assay.

[0299] The ethanol extract is a powder that is an ethanol extract of the berry. The whole berry sample is an aqueous extract from the whole berry. The samples were commercial samples of packaged freeze-dried whole berries.

[0300] discuss

[0301] These results are consistent with clematisin being the potent active substance in the samples. Figure 17 is a graph of the concentration required for 70% inhibition versus clematisin concentration. This indicates a direct correlation between clematisin content and inhibitory activity.

[0302] Table 4. Cyperus rotundus and relative MAO-B inhibitory activity of a series of blackcurrant samples.

[0303]

[0304] Example 7: Effects of a single dose of blackcurrant juice or freeze-dried powder on phytochemical bioavailability, platelet MAO-B activity, plasma neurotransmitter concentrations, and mood in healthy adults

[0305] Commissioned by Alphagen NZ Ltd, Plant and Food Research Limited conducted a randomized, double-blind, two-arm, placebo-controlled, crossover human intervention study to evaluate spatiotemporal platelet monoamine oxidase B (MAO-B) enzyme activity, phytochemical bioavailability, circulating neurotransmitters, and subjective markers of mood in participants after consuming a beverage prepared from two blackcurrant product formats (juice concentrate and freeze-dried powder). Findings from this study showed:

[0306] Anthocyanin bioavailability in plasma was detectable 10 min after consumption of the blackcurrant intervention, peaked at 120 min, and then declined at subsequent time points. Greater anthocyanin bioavailability was measured in the blackcurrant powder intervention compared with the juice concentrate intervention. This may be attributed to the higher anthocyanin dose consumed by participants assigned to the powder intervention.

[0307] The bioavailability profile of scutellarin following consumption of blackcurrant powder and juice was similar to that of anthocyanins. Despite differences in the anthocyanin doses consumed by participants assigned to the blackcurrant powder and juice groups, plasma scutellarin concentrations did not differ between the forms at any time point.

[0308] Both blackcurrant forms were equally effective in reducing peripheral platelet MAO-B enzyme activity, with reductions of -89.6% ± 2.2 and -90.5% ± 2.8, respectively. Significant enzyme inhibition was observed as early as 10 min after treatment consumption in both the juice concentrate and powder forms and persisted until the last time point of the test day (480 min after consumption).

[0309] Inhibition of platelet MAO-B by both blackcurrant forms corresponded to significant reductions in circulating concentrations of the monoamine metabolites DOPAC (a metabolite of dopamine), 5-HIAA (a metabolite of serotonin), and MHPG (a metabolite of norepinephrine). Significant reductions in circulating vanillylmandelic acid (VMA) and 3,4-dihydroxyphenylglycol (DHPG) were observed after consumption of blackcurrant juice but not powder, indicating differences in the regulatory effects between the two blackcurrant forms.

[0310] Subjective mood data collected during the study indicated the efficacy of both blackcurrant forms in improving alertness and reducing stress and mental fatigue. Greater improvements were observed in the blackcurrant powder intervention, which may be attributed to the higher doses consumed by volunteers assigned to the powder intervention.

[0311] background

[0312] Previous studies comparing the bioactivity of blackcurrant juice and blackcurrant powder suggest that delivery format (i.e., extract, freeze-dried, juice) may influence the bioactivity of blackcurrant in supporting cognition. When the anthocyanin-rich extract was consumed, the significant MAO-B inhibition detected after consuming blackcurrant juice was not observed, despite participants consuming the same relative polyphenol doses for both interventions (Watson et al. 2015). The difference in efficacy between the two food formats may be attributed to the removal or degradation of key bioactive compounds during the processing steps that produce the extract format. Therefore, food format and processing conditions are important considerations when formulating blackcurrant-based foods to obtain nootropic benefits.

[0313] Aims and Objectives

[0314] Primary objective: To characterize the temporal changes in platelet MAO-B enzyme activity after participants consumed a single serving of two different blackcurrant preparations.

[0315] Secondary objectives: To characterize the spatiotemporal blackcurrant polyphenol bioavailability, calendula glycoside bioavailability, circulating neurotransmitter concentrations, and mood parameters in participants after consuming a single serving of two different blackcurrant formulations.

[0316] method

[0317] Test drinks

[0318] This study tested two Blackcurrant (BC) product forms: juice concentrate and freeze-dried powder. Each BC form was compared with a placebo (PL) beverage that matched the appearance, flavor and texture of the corresponding BC beverage as closely as possible. BC powder and matching PL powder were provided by AlphaGen Limited (ready-to-use). BC and PL juice concentrates were formulated by the New Zealand Institute for Plant and Food Research Limited (PFR) in its food safety laboratory, with ingredients provided by AlphaGen and Sensient Technologies. BC and placebo formulations were weighed and divided into single servings in amber bottles, stored at -20°C, and then provided to participants as 300 mL beverages.

[0319] As previously agreed by AlphaGen and PFR, the total amount of BC anthocyanins contained in the two BC beverages differed between the two versions. The anthocyanin dose of the BC powder beverage (BC-P) was standardized according to the weight of each participant so that they consumed BC powder equivalent to 7.8 mg total anthocyanins / kg of their body weight, reconstituted in 300 mL of water. The placebo powder beverage (PL-P) was a placebo powder of equal weight to BC powder in 300 mL of water. Apple juice concentrate and clove extract were added to the BC and PL concentrate formulations to increase flavor complexity. Citric acid was added to both concentrate formulations, but in larger amounts for the placebo concentrate beverage (PL-JC) to match the sour taste of BC-JC. The flavor and color of PL-JC were matched to BC-JC using BC flavoring, tempting red, raspberry and blue solutions (Sensient Technologies) (Table 5). Sucrose solution (65 ° Brix) was used instead of BC juice concentrate for PL-JC.

[0320] Table 5. Components of blackcurrant and placebo juice concentrate formulations presented as single servings.

[0321]

[0322] N / A = Not applicable.

[0323] Microbial pathogen testing

[0324] The received powders and formulated juice concentrates were sent to AsureQuality Ltd for microbiological pathogen testing.

[0325] Beverage preparation

[0326] Independent researchers prepared the test beverages. The required amber bottles containing the formulations were moved to 4°C the evening before the test day. The powdered drink was prepared by mixing the powder with 300 mL of water. Water was added to the juice concentrate to equal 300 mL and stirred to combine. The test beverage was consumed by the participant within 1 hour of preparation.

[0327] Anthocyanin Quantification in Beverage Formulations

[0328] The anthocyanin concentrations of the formulated test juice concentrates and the supplied powders were measured using a Dionex Ultimate 3000 series UHPLC (ThermoFisher Scientific, San Jose, CA, USA) with PDA (photodiode array) detection at 520 nm and 530 nm. The formulated juice concentrates were diluted 1 / 1 with 5 / 95 formic acid / water (v / v). The weighed powder samples were dissolved in 5 / 95 formic acid / water (v / v) to obtain an aqueous solution with a concentration of 20 to 21 mg / mL. The detected anthocyanins were quantified using a pure standard of cyanidin 3-O-glucoside, and all results for individual anthocyanins and total anthocyanins were expressed as cyanidin 3-O-glucoside equivalents.

[0329] Clinical trials

[0330] Recruitment and Trial Registration

[0331] Thirteen healthy individuals aged 26 to 39 years recruited from the wider Palmerston North community provided informed consent to participate in this study. During recruitment, prospective participants completed a health screening questionnaire to exclude those with chronic medical conditions (e.g. heart disease, cancer), known blood-borne diseases (e.g. hepatitis), recent viral or bacterial illness, pregnancy, taking medications that affect clotting properties or mood, known intolerance to blackcurrant, or known strong reactions to needles. All methods and procedures were reviewed and approved by New Zealand's Northern B Health and Disability Ethics Committee (2021EXP 11576).

[0332] Sample size

[0333] The number of volunteers for this study was calculated using a power analysis from a previous black currant intervention study measuring peripheral MAO-B activity. Our analysis revealed that three participants would be needed in each intervention group to detect a 20% difference in MAO-B inhibition with 80% power. To account for potential participant dropouts, at least six participants were recruited per intervention group.

[0334] Study Design

[0335] The study followed a randomized, double-blind, two-arm, placebo-controlled, crossover intervention design. The flow chart of the study protocol is shown in Fig.19 and the test day program is shown in Fig. 20 Trial participants will complete two trial days, in which they will consume one of two intervention drinks (blackcurrant or placebo), with at least one week of washout in between.

[0336] Subjective feeling questionnaires and venous blood samples were collected at various time points over an 8-hour period. Participants were randomly assigned (1:1 ratio) to one of the two format groups (juice concentrate or powder) and then randomly assigned (1:1 ratio) to the order in which they received the intervention beverages. Participants and trial coordinators were unaware of which intervention beverage the participants consumed. Prior to each trial day, participants eliminated foods and supplements high in polyphenolic compounds from their diet for 24 hours. They fasted for at least 10 hours and then consumed a One Square Meal with almonds and vanilla 2 hours before the start of the trial. (Cookie Time Ltd.) as breakfast. Participants arrived at the PFR clinical facility where they were made comfortable. After a 5-min rest, they completed a visual analogue scale (VAS) subjective feelings questionnaire and then donated a venous blood sample. Thereafter, they were provided with the intervention drink and instructed to consume it as soon as possible. A VAS mood questionnaire was completed and venous blood samples were collected 10, 20, 120, 240, and 480 min after consuming the drink.

[0337] In addition to the standardized breakfast and intervention beverage, participants consumed only water and a small low-polyphenol lunch (a white bread sandwich with butter, mayonnaise, and either steamed chicken or mashed boiled eggs) for the entire 480 min. Participants were allowed to leave the clinical facility after the 20-min time point and return at a subsequent time point if they wished.

[0338] Subjective Emotion Questionnaire

[0339] The Bond-Lader visual analog emotion scale questionnaire allows for self-evaluation of emotions. A total of 16 emotion dimensions are given: alert-sleepy, calm-excited, strong-weak, confused-clear-headed, well-coordinated-clumsy, drowsy-energetic, satisfied-unsatisfied, annoyed-quiet, slow-thinking-alert, nervous-relaxed, focused-absent-minded, incompetent-skilled, happy-sad, antagonistic-friendly, interested-bored, and withdrawn-sociable. Participants are required to mark the extent to which each described state is suitable for them at that moment on the 100mm line. Individual responses from 16 emotion scales are combined to form three emotional dimensions of alertness, satisfaction, and calmness (Bond and Lader 1974). The visual analog emotion scale for stress, anxiety, and mental fatigue located on the 100mm line is used to measure the participants' current feelings of stress, anxiety, and mental fatigue, which are anchored with "not at all" on one side of the scale and "extremely" on the other side.

[0340] Biochemical analysis

[0341] Venous blood was collected from each participant into 1 × 10 mL EDTA vacutainers before (0 min) and 10, 20, 120, 240, and 480 min after beverage consumption for platelet MAO-B activity and blood glucose measurements, and into 1 × 10 mL lithium heparin tubes for plasma anthocyanin quantification.

[0342] Platelet MAO-B activity

[0343] Platelets were isolated and prepared using previously described methods (Watson et al. 2015). Briefly, platelets were isolated from whole blood (10 mL in 10% disodium EDTA solution) by centrifugation at 600 g for 3 min at 22°C without stopping. Platelets were stored at -80°C until needed. Platelets were quantified using a BCA protein assay kit (23225, Pierce TM ) to determine the protein concentration of platelet samples. The red monoamine oxidase assay kit (A12214, Invitrogen) measured MAO-B activity.

[0344] Analysis of anthocyanins and cynaroside

[0345] Plasma was separated from whole blood collected from participants in lithium heparin tubes by centrifugation at 4000×g for 10 min at 4° C. Plasma (1 mL) was spiked with 30 μL 50% formic acid and 100 μL 10 mmol ascorbic acid and then stored at −80° C. before being shipped on dry ice to the Physiological Chemistry Laboratory.

[0346] Plasma samples (350 μL) were spiked with malvidin 3-O-galactoside and further acidified with phosphoric acid before being added to SOLAμ TM Solid phase extraction plate purification. After washing with water and acetic acid, the retained anthocyanins were eluted with methanol:formic acid (95:5), evaporated to dryness, and then reconstituted in acetonitrile:formic acid:water (5:3:92) and analyzed by liquid chromatography-mass spectrometry (LC-MS). Quantification of individual and total anthocyanins was performed using MultiQuant software using the internal standard ratio method, and all results are reported as cyanidin 3-O-glucoside equivalents. Quantification of cynaroside was performed using external reference standards supplied by Stephen Bloor (Callaghan Institute).

[0347] Neurotransmitter analysis

[0348] A total of 111 plasma samples were analyzed, and the total number of samples available for each intervention type / intervention format / time point ranged from n=3 to n=7. The method used for neurotransmitter analysis utilized an MS probe and stable isotope-coded LCMS method developed in-house at Plant and Foods that was optimized for plasma samples (Parkar et al., 2020; Watson et al., 2020). The neurotransmitter method included extensive coverage of inhibitory and excitatory neurotransmitters from tyrosine, tryptophan, and glutamate metabolic pathways involved in the gut-brain axis. Briefly, the metabolites measured in the tyrosine metabolic pathway are phenylethylamine (PEA), tyrosine (TYR), 3,4-dihydroxyphenylalanine (L-DOPA), dopamine (DA), 3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), norepinephrine (NE), 3,4-dihydroxyphenylethylene glycol (DHPG), 3-methoxy-4-hydroxyphenylethylene glycol (MHPG), normetanephrine (NM), epinephrine (E), metanephrine (MN), and vanillylmandelic acid (VMA). In the tryptophan metabolic pathway are tryptophan (TRP), kynurenine (KYN), kynurenic acid (KA), xanthurenic acid (XA), quinolinic acid (QA), 5-hydroxytryptophan (5-HTP), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), and melatonin (MT). In addition, for glutamate metabolism, the metabolites measured were glutamate (GLU), α-aminobutyric acid (AABA), and γ-aminobutyric acid (GABA).

[0349] Other endogenous analytes relevant to the gut-brain axis measured were glycine (GLN), serine (SER), histamine (HIS), adenosine (ADO), and cortisol (CORT). Prior to LC-MS analysis, samples were derivatized in three stages to acetylate alcohol and amine functional groups and alkylate carboxylic acid groups. A multiple derivatization strategy was found to be required to acetylate the less reactive alkyl hydroxyl and carboxylic acid groups. Deuterated internal standards (IS) for the analytes were added at the beginning of sample workup to correct for recoveries.

[0350] To facilitate quantification and correct for matrix effects during analysis, labeled IS (IS-XdP) for each analyte was prepared by derivatization of a mixed neurotransmitter standard as described for the samples, except that deuterated acetic anhydride [d6] and deuterated trifluoroethanol [d3] were used instead of unlabeled acetic anhydride and unlabeled trifluoroethanol. After sample workup, the IS-XdP standards were added to the samples.

[0351] Briefly, acetic anhydride, sodium bicarbonate / sodium carbonate buffer, acetonitrile, and mixed IS containing deuterated analytes were added to each plasma sample (100 μL). The samples were evaporated to dryness overnight and then derivatized with acetic anhydride and trifluoroethanol at 70°C for 4 h, and the temperature was reduced to 50°C and then allowed to react overnight. The samples were dried again and further derivatized with acetic anhydride, and then water, acetonitrile, and IS-XdP were added. The samples were filtered through a 96-well glass fiber plate and collected in a 96-deep-well polypropylene plate and then analyzed by LCMS. The samples were analyzed on a Turbo V equipped with a Shimadzu Nexera LC40 UHPLC (Shimadzu, Tokyo, Japan) coupled to a Shimadzu Nexera LC40 UHPLC (Shimadzu, Tokyo, Japan). TM LCMS experiments were performed on a 7500QTrap triple quadrupole / linear ion trap (QqLIT) mass spectrometer with an ion source and electrospray ionization (ESI) probe (AB Sciex, Concord, ON, Canada). MS data were acquired in positive mode using a multiple reaction monitoring (MRM) approach.

[0352] blood sugar

[0353] use 201DM System( Sweden) blood glucose analyzer to measure the blood glucose concentration in whole blood.

[0354] statistics

[0355] Chemical data presented in this report are mean ± standard error of the mean. Monoamine oxidase-B activity, subjective measures, and glucose data are presented as mean ± standard error of the mean. Comparisons of means between time points, treatments, and types were performed using analysis of variance (ANOVA) from a linear mixed-effects model, with type, study day, treatment, time, and their interactions as fixed effects, and participant, participant × study day, participant × treatment, and participant × time point as random effects. Models were fitted using the R package lmerTest, and the least significant difference (LSD) for comparison of means was calculated post hoc using the R package predictmeans. Statistical significance for all measures was set at p < 0.05 with a confidence level of 95%.

[0356] Neurotransmitter data analysis

[0357] R 4.2.1 version is used for the analysis and data visualization of neurotransmitter results.All observations are standardized to the difference of the first measurement value with time course (0min).The Spearman rank and correlation matrix of standardized neurotransmitter concentration and MAO-B inhibition is calculated for each condition using software package "PerformanceAnalytics".The one-dimensional graph of the variable of the significant correlation of MAO-B inhibition in the intervention type and their corresponding correlation coefficient in the placebo type is displayed using R base function visualization.Adopt multivariate method, use standardized, centered with median and scaled neurotransmitter concentration as variable.Use "factoMineR" software package, carry out principal component analysis, and the variable load with the strongest contribution to component 1 and 2 is visualized as relevant circular graph.

[0358] For univariate statistical analysis of standardized neurotransmitters, linear mixed-effect models were calculated using the R package "lmerTest" to simultaneously consider fixed and random effects of multiple factors. The fitted model had fixed effect factors for formulation (powder vs. juice), treatment (blackcurrant vs. placebo), and time; random effects were participant, participant×treatment, and participant×time.

[0359] Each participant received only one formulation, so a random effect of participant x formulation was not required. In cases where ANOVA indicated a significant (p<0.01) treatment effect or interaction, predicted means were obtained and pairwise comparisons were performed with Fisher's least significant difference (LSD, α=0.05) calculations using the "predictmeans" package.

[0360] result

[0361] Anthocyanin content in juice and powder

[0362] The blackcurrant anthocyanin content of the test juice concentrate and powder formulated before adding water (to make a 300 mL beverage) is shown in Table 6. Based on the total anthocyanin results, the blackcurrant juice concentrate contained 2179.4 μg / g wet weight total anthocyanins, and the blackcurrant powder contained 33720.4 μg / g dry weight total anthocyanins. The placebo juice concentrate and powder formulations contained no detectable blackcurrant anthocyanins.

[0363] Table 6. Blackcurrant anthocyanin content in blackcurrant juice concentrate and placebo juice concentrate, and blackcurrant powder and placebo powder. Juice concentrate is reported in μg / g wet weight and powder is reported as is in μg / g dry weight. nd: not detected.

[0364]

[0365]

[0366] Trial Participants

[0367] Ten of the 13 participants recruited completed both trial days ( Fig.19 ). The data of three participants who did not complete both trial days were not included in the analysis for this report. The anthropometric data of the ten participants are shown in Table 7. Of these ten, five were assigned to the juice concentrate form and five were assigned to the powder form. Although some participants withdrew from the trial, the number of participants who completed both trial days was within the range required to detect statistically significant MAO-B enzyme inhibition from consumption of the blackcurrant form.

[0368] Participant withdrawal and reactions

[0369] Table 7. Anthropometric characteristics of participants in both format groups: juice concentrate and powder. Data are mean ± SEM, and minimum and maximum values ​​from n = 5 individuals per group.

[0370]

[0371] Of the three participants who did not complete both trial days, one participant requested to withdraw after completing the first day; one participant withdrew after having a strong reaction to the needle; and another participant withdrew after having a transient adverse gastrointestinal reaction to the intervention drink.

[0372] Total anthocyanins dosage

[0373] Because each modality uses different dose standardization, participants were The absolute anthocyanin doses consumed in the blackcurrant intervention were not equal (Table 8). Participants in the BC-JC group all consumed 300 mL of a single strength blackcurrant juice, whereas participants in the BC-P group consumed a standardized dose of anthocyanins (7.8 mg total anthocyanins / kg body weight). Thus, participants in the PC-P group consumed approximately 7.8 times more anthocyanins per kg body weight than volunteers in the BC-JC group.

[0374] Table 8. Average consumption of blackcurrant formulations and total anthocyanins per type group. Data are mean ± SEM from n = 5 individuals per type group.

[0375]

[0376] *No additional water.

[0377] Bioavailability of anthocyanins and cynaroside

[0378] The concentrations of total anthocyanins, cyanidin methyl glucuronide, cyanidin 3-O-rutinoside, cyanidin 3-O-glucoside, delphinidin 3-O-rutinoside, and delphinidin 3-O-glucoside were measured in plasma after consumption of black currant intervention ( Fig.21 ). Blackcurrant anthocyanins could not be detected in the plasma of the placebo (PL) intervention (data not shown). Anthocyanin concentrations in BC-P plasma were higher than those in BC-JC for all time points measured after consumption. The maximum total anthocyanin concentrations in plasma were 25.7±4.1 nM and 3.6±0.4 nM for BC-P and BC-JC, respectively. Peak concentrations of all anthocyanins were measured at 120 min for both types.

[0379] The bioavailability of scutellaria baicalensis in plasma after consumption of BC beverage was shown in Fig. 22 Similarly, for anthocyanin bioavailability, the peak concentration of clematisin was measured at 120 min. The bioavailability profile of clematisin was similar in both types. However, it should be noted that the analytical method was not optimized for clematisin and the recovery of clematisin by the cleanup protocol was poor. Therefore, while the relative concentrations of clematisin measured for the two BC types can be used to inform the bioavailability profile, the absolute clematisin concentrations may be under-reported. Any further analysis should employ a stepwise cleanup protocol for anthocyanins and clematisin, as well as separate LC-MS analysis.

[0380] MAO-B Inhibition and Blood Glucose

[0381] edible Blood glucose concentrations and platelet MAO-B enzyme activity after blackcurrant and placebo intervention were shown in Fig.23ANOVA using a mixed effects model (Table 9) revealed that form (i.e., powder or granules) had no significant effect on MAO-B enzyme activity (p=0.561). However, significant treatment (BC vs. placebo) (p=0.011), time (p<0.001), and treatment×time (p<0.001) interactions were detected.

[0382] Table 9. Analysis of variance (ANOVA) results from a mixed effects model to determine the effects of pattern, treatment, time, and treatment x time interaction on MAO-B enzyme activity and blood glucose after consumption of the test beverages. Data are F values ​​and p values, where p<0.05 indicates a significant effect.

[0383]

[0384] MAO-B activity was reduced after consumption of all test beverages, but was significantly reduced from baseline (0 min) 10 min after consumption of the blackcurrant beverage (-76.1% ± 7.9 and -75.9% ± 9.7, respectively; BC-JC, BC-P). Maximum MAO-B inhibition was measured for both types at 20 min after consumption (-89.6% ± 2.2, -90.5% ± 2.8, respectively, BC-JC, BC-P) and was maintained at this level until 120 min. The significant inhibition of MAO-B persisted for the duration of the study, such that at 480 min after consumption, the enzyme activity was significantly reduced in both blackcurrant types (-35.3% ± 11.9 and -38.3% ± 11.7, respectively; BC-JC, BC-P).

[0385] Small but significant decreases in MAO-B activity from baseline were measured after consumption of both placebo formulations, with maximal inhibition of these beverages being -8.6% ± 6.2 and -21.0% ± 6.3 at 480 min and 240 min for PL-JC and PL-P, respectively.

[0386] Statistical analysis (Table 9) revealed a significant time effect on blood glucose concentration (p = 0.043). On average, blood glucose concentrations generally increased after consuming the test beverages (10min and 20min) and remained above baseline concentrations during the remaining time points. No significant changes in blood glucose were observed after consuming the powdered beverages (BC-P and PL-P). In contrast, significant increases in blood glucose from baseline (0min) concentrations were measured after consuming PL-JC (10min and 20min) and BC-JC (20min, 120min, and 480min).

[0387] VAS subjective mood score

[0388] Bond-Lader Questionnaire

[0389] Table 10. Analysis of variance (ANOVA) results from a mixed effects model to determine the effects of type, treatment, time, and their interactions on descriptive items related to alertness after consumption of the test beverages. Data are F values ​​and p values, where p<0.05 indicates a significant effect.

[0390]

[0391] Table 11. Analysis of variance (ANOVA) results from a mixed effects model to determine the effects of type, treatment, time, and their interactions on descriptive items related to satisfaction and calmness (tension / excitement and tension / relaxation) after consuming the test beverages. Data are F values ​​and p values, where p<0.05 indicates a significant effect.

[0392]

[0393] For the descriptors related to alertness, a significant time interaction was observed for the sleepiness / energetic scores, and a significant modality×treatment×time interaction was measured for the interest / boredom scores. For the remaining alertness-related items, no significant effects of modality, time, treatment, or their interactions were observed.

[0394] A significant treatment × time interaction was observed for the unfriendly / friendly rating measure. Significant type × treatment × time interactions were also measured for happy / sad and unfriendly / friendly (items related to satisfaction). A significant type × treatment × time interaction was also observed for calm / excited ratings (descriptors related to satisfaction).

[0395] Fig.24 Descriptive items from the Bond-Lader questionnaire that were found to have a significant Type × Treatment × Time interaction are plotted in . Significantly (p < 0.05) higher interest / boredom and calm / excitement scores were observed in the BC-JC compared to the PL-JC intervention after 120 min and 480 min, respectively. No significant differences were observed between the BC-P and PL-P for these items at the same time points.

[0396] Table 12. Analysis of variance (ANOVA) results from a mixed effects model to determine the effects of type, treatment, time, and their interactions on alertness, calmness, and satisfaction after consuming the test beverages. Data are F values ​​and p values, where p<0.05 indicates a significant effect.

[0397]

[0398]

[0399] When descriptive items from the Bond-Lader questionnaire were categorized to give composite scores of alertness, calmness, and satisfaction, a significant time effect was observed for alertness, but not for calmness and satisfaction. For these categories, no significant modality, treatment, treatment × time, and modality × treatment × time interactions were detected.

[0400] Table 13. Alertness, calmness and satisfaction scores (from the Bond-Lader Questionnaire) after consumption of blackcurrant juice or powder and their corresponding placebos. Values ​​are means ± SEM.

[0401]

[0402] * indicates a significant difference from 0 min (p<0.05). ^ indicates a significant difference from placebo at the corresponding time point (p<0.05).

[0403] Participants' alertness scores increased significantly 20 minutes after consuming the PI-JC intervention, and then decreased thereafter, such that alertness scores at 480 minutes were significantly lower than baseline (0 minutes) scores (Table 11). After consuming BC-JC, there were no significant changes in alertness scores relative to baseline (0 minutes) at any time point. For the powder form, alertness scores were significantly higher than baseline (0 minutes) scores 20 minutes after consuming the PL-P intervention. Significant increases in alertness were also observed at 10 minutes, 20 minutes, and 120 minutes after consuming BC-P. In addition, the BC-P alertness score at 120 minutes after consumption was significantly higher than the placebo (PL-P) score at this time point.

[0404] Mean calmness was significantly higher 480 min after consumption of the juice placebo drink (PL-JC), whereas significantly lower calmness was measured at this time point after drinking blackcurrant juice (BC-JC), resulting in significant differences in calmness scores between treatment groups at this time point (p<0.05) (Table 11). A significant increase in calmness was measured 20 min after consumption of PL-P, whereas no change in calmness was measured in the BC-P intervention group. Calmness scores in PL-P at 20 min after consumption were significantly higher than calmness scores in the BC-P intervention at this time point.

[0405] An immediate increase in satisfaction scores from baseline (0 min) was measured in the PL-JC intervention group (Table 11). This trend was also observed in the BC-JC group, with significantly higher satisfaction scores at 20 min and 480 min after drinking the beverage. For the powdered form, neither beverage (PL-P or BC-P) resulted in a significant change in satisfaction scores at any time point measured.

[0406] Stress, anxiety and mental fatigue

[0407] Table 14. Analysis of variance (ANOVA) results from a mixed effects model to determine the effects of type, treatment, time, and their interaction on stress, anxiety, and mental fatigue after consumption of the test beverages. Data are F values ​​and p values, where p<0.05 indicates a significant effect.

[0408]

[0409] No significant pattern, treatment or time effects were observed for subjective measures of stress, anxiety or mental fatigue (Table 14). However, there were significant treatment × time effects for stress (p = 0.021) and mental fatigue (p = 0.013). A near-significant pattern × treatment × time interaction was detected for stress (p = 0.051), but not for anxiety and mental fatigue.

[0410] Neither of the two types of placebo interventions tested in this study (PL-JC and PL-P) had a significant effect on subjective stress scores. A significant decrease in stress scores was observed after consumption of BC-JC (20 min and 240 min) and BC-P (20 min, 120 min, and 480 min). No significant treatment differences in stress scores were observed between PL-JC and BC-JC at any measurement time point. In contrast, the BC-P group had significantly higher stress scores measured at baseline (0 min), 10 min, 20 min, and 240 min than the PL-P group.

[0411] No significant changes in anxiety scores were observed after consumption of either of the powder interventions (PL-P and BC-P). However, anxiety scores were significantly lower than baseline (0 min) scores at 10 min and 480 min after consumption of PL-JC and BC-JC. At these time points, significantly higher anxiety scores were measured at baseline (0 min), 10 min, and 20 min in the BC-P group than in the corresponding placebo intervention (PL-P).

[0412] No significant changes in mental fatigue scores were observed after consuming BC-JC, while a significant increase in this parameter was observed at 240 min and 480 min after consuming the placebo intervention (PL-JC). In contrast, consuming the placebo powder (PL-P) had no significant effect on the mental fatigue scores, while a significant decrease from the baseline (0 min) score was measured at 20 min, 120 min, and 240 min after consuming the BC-P intervention. In addition, the mental fatigue scores at baseline (0 min) and 480 min after consuming BC-P were significantly higher than the scores after consuming the placebo (PL-P) at these time points.

[0413] Table 15. Stress, anxiety and mental fatigue responses (on a 100 mm visual analogue scale (VAS) anchored with "not at all" and "extremely" at either end) after consumption of blackcurrant juice or powder and their corresponding placebos. Values ​​are mean ± SEM for each parameter.

[0414]

[0415]

[0416] * indicates a significant difference from 0 min (p<0.05). ^ indicates a significant difference from placebo at the corresponding time point (p<0.05).

[0417] Circulating neurotransmitter concentrations

[0418] Concentrations of 32 endogenous neurotransmitters and other compounds associated with the gut-brain axis were measured in the plasma of 13 participants. Of the ten participants who completed both trial days (including the blackcurrant intervention and the placebo intervention), five participants (four receiving the juice form and one receiving the powder form) had samples collected at each time point. An additional three participants, all receiving the powder form, had one missing time point for each trial day. The remaining five participants completed only the blackcurrant intervention day, with two participants receiving the juice form and three receiving the powder form.

[0419] The analysis of variance revealed significant (p<0.01) treatment×time interactions for five neurotransmitter metabolites related to the tyrosine metabolic pathway (PHE, DOPAC, DHPG, MHPG, and VMA) and 5-HIAA (a neurotransmitter from the tryptophan metabolic pathway) (Table 16). The pattern×treatment×time interactions were also tested for PHE, NE, KA, and GLU.

[0420] Table 16. Analysis of variance (ANOVA) results from a mixed effects model to determine the effects of treatment and time and their interactions on circulating neurotransmitters associated with tyrosine, tryptophan, and glutamate metabolic pathways after consumption of the test beverages. Data are F values ​​and p values. Significant (p < 0.01) treatment × time effects are shown in bold and highlighted in red.

[0421]

[0422]

[0423] Phenylethylamine, PEA; phenylalanine, PHE; tyrosine, TYR; 3,4-dihydroxyphenylalanine, L-DOPA; dopamine, DA; 3-methoxytyramine, 3-MT; 3,4-dihydroxyphenylacetic acid, DOPAC; homovanillic acid, HVA; norepinephrine, NE; 3,4-dihydroxyphenylethylene glycol, DHPG; 3-methoxy-4-hydroxyphenylethylene glycol, MHPG; normetanephrine, NM; metanephrine, MN; vanillylmandelic acid, VMA; tryptophan, TRP; kynurenine, KYN; kynurenic acid, KA; xanthurenic acid, XA; quinolinic acid, QA; 5-hydroxytryptophan, 5-HTP; serotonin, 5-HT; 5-hydroxyindoleacetic acid, 5-HIAA; melatonin, MT; glutamate, GLU; alpha-aminobutyric acid, AABA; and gamma-aminobutyric acid, GABA. Other endogenous analytes relevant to the gut-brain axis (GBA) measured were glycine, GLN; serine, SER, histamine, HIS; adenosine, ADO; and cortisol, CORT.

[0424] To identify whether any modulation of plasma neurotransmitter concentrations might be associated with MAO-B inhibition, paired rank sum correlation tests were performed. Four neurotransmitters from the tyrosine metabolic pathway (DOPAC, VMA, HVA, and DA), and one neurotransmitter from the tryptophan metabolic pathway (5-HIAA) showed significant positive correlations with MAO-B inhibition after consumption of blackcurrant juice forms ( Fig.25 ). The same correlation was not significant for the placebo intervention. With the exception of DA, these neurotransmitters are all MAO-derived metabolites and suggest a downstream effect of BC-induced MAO-B inhibition on circulating neurotransmitter concentrations.

[0425] In addition to DOPAC, these same neurotransmitters also showed significant positive correlations with MAO-B inhibition after consumption of blackcurrant powder, which were not observed with placebo. Significant correlations with MAO-B inhibition were also observed for metabolites XA, MN, NM, and KA from the tryptophan metabolic pathway for the powder intervention form only. NM is a substrate for MAO-A / B, while XA, MN, and KA are not substrates or metabolites of MAO-A / B.

[0426] The temporal changes in plasma neurotransmitter concentrations from the tyrosine metabolomics pathway after consumption of BC-JC and BC-P interventions and their placebos are plotted in Figure 26. Plasma DOPAC was significantly lower 120 min after consumption of BC-JC and BC-P compared to the placebo group at the same time point ( Figure 26A-26B). At these time points, plasma VMA concentrations were significantly lower at 120 min and 240 min after consuming BC-JC but not BC-P compared to the placebo group (Figure 26E-Figure 26F). Although plasma HVA and DA concentrations tended to be lower after consuming BC-JC and BC-P compared to the corresponding placebo, no significant treatment differences were measured for these neurotransmitters at any time point.

[0427] Blackcurrant consumption was also found to modulate plasma concentrations of 5-HIAA (a tyrosine metabolite) in both temporal and spatial directions ( Fig. 27 ). Significantly lower plasma 5-HIAA concentrations were measured as early as 10 min after consuming BC-P compared to the placebo group, which persisted until 240 min. This near-immediate effect was not measured in the BC-JC group, where significant decreases in plasma 5-HIAA were observed at 120 min and 240 min compared to the placebo group. Correlation analysis also revealed significant correlations between XA, MN, NM, and KA and MAO-B for BC-P alone. Further ANOVA analysis revealed no significant time and treatment interactions for these neurotransmitters after consuming BC-P at any of the measured time points ( Fig.28 ).

[0428] Although not significantly associated with MAO-B inhibition, univariate ANOVA analysis revealed significant time × treatment interactions for neurotransmitters (MHPG, DHPG, and PHE) (Table 17). Fig.29 The relative changes of these neurotransmitter concentrations after consuming BC-JC and BC-P are drawn in to illustrate the changes of the effects of the types on these neurotransmitters. Compared with the placebo group, significantly lower plasma MHPG concentrations were measured at 120min after consuming BC-JC and BC-P. However, at these time points, compared with the placebo group, consuming a single dose of BC-JC but not BC-P significantly reduced plasma DHPG (120-240min) and PHE (20-240min).

[0429] To further explore which neurotransmitter combinations might drive changes between time points for both blackcurrant forms compared to placebo, a multivariate approach was used. Fig.30 ) shows the correlations among the top 12 variables that contribute most to the principal components. Fig.30 A shows the major contribution of 5-HIAA in driving changes in neurotransmitter concentrations during the time course experiment associated with the blackcurrant interventions (juice and powder combination). It further demonstrates strong interactions between 5-HIAA, HVA, VMA and correlations with DOPAC and MHPG. These correlations were not observed for the placebo intervention ( Fig.30 B).

[0430] discuss

[0431] This study demonstrates that, despite different anthocyanin doses consumed by participants in two different BC form groups (juice concentrate and powder), consumption of a single 300 mL beverage prepared from either form resulted in equivalent inhibition of platelet MAO-B enzyme activity. Blackcurrant anthocyanins were detectable in plasma 10 min after consumption of both forms, peaking at 120 min, and then gradually declining to near baseline concentrations 480 min after consumption. Higher concentrations of individual and total anthocyanins were measured in plasma after consumption of BC powdered beverages compared to BC juice concentrate beverages. In contrast, no differences in the bioavailability of scutellaria scutellaria glycosides were measured between the two blackcurrant forms at any time point. Significant changes in plasma neurotransmitter concentrations were measured after consumption of BC juice concentrate and BC powdered beverages compared to placebo. The findings also suggest that the efficacy of consuming blackcurrant in regulating participants' mood or other beneficial cognitive factors is achieved, at least in part, through MAO enzyme inhibition via scutellaria scutellaria glycoside activity.

[0432] The concentrations of cyanidin and delphinidin derivatives measured in the plasma of BC-P were approximately 7 times higher than those of BC-JC. This difference in bioavailability was attributed to the different doses of anthocyanins consumed by the participants: on average, the dose of anthocyanins consumed by the participants in the BC-P group was almost eight times the amount consumed by the participants in the BC-JC group. Despite the different doses, the spatiotemporal bioavailability profiles of total and individual anthocyanins during the test days were similar for BC-P and BC-JC, indicating that the absorption rates of the two forms of anthocyanins are similar.

[0433] The bioavailability of clematisin in plasma samples was also measured using standards provided by Stephen Bloor from Callaghan Innovation. The bioavailability of clematisin in plasma following consumption of both blackcurrant types was similar and followed the same bioavailability profile as the anthocyanins. Interestingly, despite the large differences in the doses of anthocyanins consumed, the bioavailability of clematisin at each measured time point was similar between types. It should be noted that the recovery of clematisin in all plasma samples was low and the clematisin results presented in this report are not corrected for recovery. Further work is required to improve the method and increase the recovery of clematisin in plasma to more accurately quantify clematisin in plasma.

[0434] The present study demonstrated a rapid, sustained and significant reduction in peripheral platelet MAO-B activity after consumption of a single dose of the tested blackcurrant beverages (BC-JC and BC-P). The inhibition of MAO-B activity in platelets was also consistent with the bioavailability profile of anthocyanins in plasma. MAO-B activity was associated with an increase in anthocyanin bioavailability in plasma, whereas a decrease in bioavailable anthocyanins 120 min after consumption of BC was accompanied by a decrease in MAO-B inhibition.

[0435] Although MAO-B inhibitory bioactivity of anthocyanins cannot be ruled out, it seems likely that the significant platelet MAO-B inhibition observed in these clinical studies may be largely attributable to black currant components other than anthocyanins, such as calendula.

[0436] Subjective data analysis indicated a potential role for BC beverages in regulating mood, with increased plasma levels of scutellariae concentrations, as well as MAO enzyme inhibition. Compared with placebo, consumption of blackcurrant juice and powder reduced participants' stress and anxiety to varying degrees, reduced participants' calmness, and maintained or significantly reduced subjective scores of mental fatigue. Greater reductions in stress, anxiety, and mental fatigue were measured in the BC-P group compared to the BC-JC group. A general increase in alertness was measured immediately after drinking all beverages, followed by a gradual decrease in alertness over the course of the test day.

[0437] Alertness measured after BC-JC remained consistent over the course of the trial day, whereas alertness after PL-JC fell below baseline values ​​at 480 min. And alertness after BC-P remained elevated and was significantly higher than after PL-P at 120 min. Taken together, these findings suggest that blackcurrant consumption improved alertness or prevented a decline in alertness over the course of the trial day.

[0438] In most mammalian tissues, including humans, MAO exists in two subtypes (MAO-A and MAO-B), which show regional differences in enzyme activity, substrate specificity, and distribution in the brain and periphery (Yeung et al., 2019). It is reported that 5-HT is preferably degraded by MAO-A, while MAO-B exhibits a higher affinity for benzylamine and PEA. Catecholamines such as DA, E, NE, tryptamine, and 3-MT are substrates for both subtypes (Goldstein et al., 2021). In addition, plasma concentrations of DHPG and MHPG have been described as sensitive indicators of MAO-A-dependent metabolism of NE (Scheinin et al., 1991).

[0439] Initial multivariate analysis identified five neurotransmitters that showed significant associations with MAO-B inhibition under both juice and powder form interventions, and an additional four neurotransmitters that showed significant associations only for the powder form. Three neurotransmitters (5-HIAA, DOPAC, and VMA) showed consistent treatment × time effects that were statistically significant only on the juice form. Further analysis identified strong interactions between 5-HIAA, HVA, VMA, and associations with DOPAC and MHPG. Our findings also confirmed significant treatment × time effects for MHPG and its precursor DHPG, although the latter only reached significant levels for the juice form. The treatment × time effect of HVA (p=0.024) was not statistically significant, but the changes in concentration profiles were very similar to those observed for VMA, particularly for the juice intervention form. The significant changes in concentrations of each of these analytes were greatest at 120 min after treatment ingestion, with plasma concentrations in the blackcurrant group lower relative to placebo. Notably, the neurotransmitters highlighted by our analysis are all end products of neurotransmitters metabolized by MAO as part of the tyrosine and tryptophan metabolic pathways.

[0440] Interestingly, the decrease in circulating concentrations of 5-HIAA and MHPG / DHPG after blackcurrant consumption suggests a benefit of blackcurrant in inhibiting both MAO-A and MAO-B activity.

[0441] Although both blackcurrant juice and powder interventions inhibited platelet MAO-B activity to a similar extent, some differences in the regulation of neurotransmitters were observed between the two formats. Neurotransmitters (VMA, DHPG, and PHE) were significantly reduced after consumption of BC-JC, but not after consumption of BC-P, even though the BC-P intervention group consumed a higher dose of anthocyanins. It is possible that these differences could be minimized by testing the efficacy of these formats with a larger sample size. It also seems likely that these format differences can be attributed to changes in bioactive substances other than anthocyanins between the juice and powder formats.

[0442] The small sample size of participants enrolled in each BC modality is an important limitation to consider when interpreting mood and neurotransmitter data. The number of participants recruited to this study was based on detecting differences in MAO-B inhibition as the primary outcome, and mood and neurotransmitter data as secondary outcomes. Given this limitation, a rigorous approach was taken in our final analysis of neurotransmitter outcomes to determine if any treatment effects or interactions were statistically significant (p<0.01). Another limitation is the uncontrolled environmental influences that may have influenced participants’ mood during the trial days, as they were allowed to choose to enter and exit the facility after the 20-min data collection time point.

[0443] The significant difference in blood glucose concentration measured between BC-JC and PL-JC may be attributed to the difference in sugar content between the two interventions. To ensure that the sugar content between the two doses was equal, we formulated BC-JC and PL-JC to the same soluble solids content (measured as °Brix). However, it should be noted that Brix is ​​only an approximate measure of sugar content and may be affected by other solids present in the solution. Anthocyanins are also known to regulate blood glucose concentration (Kim et al., 2016), which may partially explain the reduction in blood glucose concentration observed in the anthocyanin-rich BC-JC intervention compared to the PL-JC intervention.

[0444] Conclusion and future work

[0445] Results showed very similar bioavailability profiles between the blackcurrant juice concentrate and powder interventions, albeit of different magnitudes. The spatiotemporal bioavailability of scutellarin, the specific metabolite of interest in this study, also followed very similar bioavailability profiles between the two blackcurrant forms until 480 min post-consumption.

[0446] The results demonstrate that consumption of beverages prepared from blackcurrant powder and juice concentrate reduces platelet MAO-B enzyme activity to the same magnitude and at the same rate, despite the different formats and dosing methods used for each format. To the best of applicants' knowledge, this is the first study to demonstrate the efficacy of blackcurrant powder in inhibiting platelet MAO-B to the same extent as blackcurrant juice. The MAO-B activity data combined with the bioavailability data indicate that lower doses of blackcurrant anthocyanins in beverages formulated from juice concentrate cause comparable MAO-B inhibition to higher doses of blackcurrant anthocyanins from beverages formulated from blackcurrant powder.

[0447] The inhibition of platelet MAO-B activity after a single dose of BC juice or powder was also accompanied by a significant transient reduction in circulating monoamine neurotransmitters (DOPAC, 5-HIAA, and MHPG). We also observed an effect of format on monoamine neurotransmitters, with statistically significant reductions in circulating VMA and DHPG after consumption of BC juice but not BC powder. The reasons supporting these format effects are unclear but may be attributed to the small sample size of this study or compositional differences between the two formats.

[0448] Subjective data collected during this study indicated that blackcurrant consumption was beneficial in reducing resting stress, anxiety, and mental fatigue, as well as improving alertness.

[0449] References

[0450] Watson AW, Haskell-Ramsay CF, Kennedy DO, Cooney JM, Trower T, Scheepens A. Acute supplementation with blackcurrant extracts modulates cognitive functioning and inhibits monoamine oxidase-B in healthy young adults. J Funct Foods 2015;17:524–39.

[0451] Watson AW, Scheepens A, Kennedy DO, Cooney JM, Trower TM, Haskell-Ramsay CF. "The pharmacodynamic profile of "Blackadder" blackcurrant juice effects upon the monoamine axis in humans: A randomised controlled trial." Nutr Neurosci. 2020 Jul;23(7):516-525. doi:10.1080 / 1028415X.2018.1525950. Epub 2018 Oct 5. PMID:30289026.

[0452] Herraiz, T., Chaparro, C. (2006) Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by β-carboline alkaloids occurring in foods and plants. Journal of Chromatography A 1120 (1-2), pp. 237-243

[0453] Herraiz, T., Flores, A., Fernández, L. (2018). Analysis of monoamine oxidase (MAO) enzymatic activity by high-performance liquid chromatography-diode array detection combined with anassay of oxidation with a peroxidase and its application to MAO inhibitors from foods and plants. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 1073, pp. 136-144

[0454] Blech, S., Budzikiewicz, H., Dill, D. (1994). β-Carboline Alkaloids from Ribes nigrum L. Zeitschrift fur Naturforschung-Section C Journal of Biosciences. 49(9-10), pp. 540-544

[0455] Yamada M, Yasuhara H. Clinical alpharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004 Jan;25(1-2):215-21. doi:10.1016 / S0161-813X(03)00097-4. PMID:14697896.

[0456] Delumeau JC, Bentué-Ferrer D., Gandon JM, Amrein R., Belliard S., Allain H. (1994) Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. In: Tipton K.F., Youdim MBH, Barwell CJ, Callingham BA, Lyles GA (eds.) Amine Oxidases: Function and Dysfunction. Journal of Neural Transmission, Vol. 41. Springer, Vienna.

[0457] Cai, Z. "Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review)". Molecular Medicine Reports 9, No. 5 (2014): 1533-1541.

[0458] Carradori S, Secci D, Petzer JP. MAO inhibitors and their wider applications: a patent review. Expert Opin Ther Pat. 2018 Mar;28(3):211-226. doi:10.1080 / 13543776.2018.1427735. Epub 2018 Jan 17. PMID: 29324067.

[0459] Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull. 1991; 27(4): 493-502. PMID: 1813896.

[0460] Herraiz T. Identification and occurrence of beta-carboline alkaloids in raisins and inhibition of monoamine oxidase (MAO). J Agric Food Chem. 2007 Oct 17;55(21):8534-40. doi:10.1021 / jf0719151. Epub 2007 Sep 21. PMID:17883257.

[0461] Dingemanse J, Wood N, Jorga K, Kettler R. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Br J Clin Pharmacol. 1997 Jan;43(1):41-7. PMID:9056051.

[0462] Lu Y, Foo LY, Wong H. Nigrumin-5-p-coumarate and nigrumin-5-ferulate, two unusual nitrile-containing metabolites from blackcurrant (Ribes nigrum) seed. Phytochemistry. 2002 Feb;59(4):465-8. doi:10.1016 / s0031-9422(01)00441-1. PMID:11830168.

[0463] Fernandes JM, Terminzi A, Mandova T, Hammad K, Machera K, Magiatis P, Michel S, Zucolotto SM, Grougnet R. Detection, Isolation, and 1H NMR Quantitation of the Nitrile Glycoside Sarmentosin from a Bryophyllum pinnatum Hydro-Ethanolic Extract. J Agric Food Chem. 2021 Jul 28;69(29):8081-8089. doi:10.1021 / acs.jafc.1c01414. Epub 2021 Jul 19. PMID:34279926.

[0464] Anima Ghosal, Chapter 8 - Evaluation of the clearance mechanism of non-CYP-mediated drug metabolism and DDI as a victim drug, edited by Shuguang Ma, Swapan K. Chowdhury, Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters (2nd ed.), Elsevier, 2020, pp. 237-271, ISBN 9780128200186, https: / / doi.org / 10.1016 / B978-0-12-820018-6.00008-9.

[0465] Bond A,Lader M 1974. The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology 47(3):211-218.

[0466] Goldstein DS, Castillo G, Sullivan P, Sharabi Y 2021. Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases. J Pharmacol Exp Ther 379(3):253-259.

[0467] Kim Y, Keogh JB, Clifton PM 2016. Polyphenols and Glycemic Control. Nutrients 8(1).

[0468] Lomiwes D, Ha B, Ngametua N, Burr NS, Cooney JM, Trower TM, Sawyer G, Hedderley D, Hurst RD, Hurst SM 2019. Timed consumption of a New Zealand blackcurrant juice support positive affective responses during a self-motivated moderate walking exercise in healthy sedentary adults. J Int SocSport Nutr 16(1).

[0469] Parkar SG, Jobsis CMH, Trower TM, Cooney JM, Hedderley DI, Bentley-Hewitt KL 2020. Bioaminergic Responses in an In Vitro System Studying Human Gut Microbiota-Kiwifruit Interactions. Microorganisms 8(10).

[0470] Scheinin M, Karhuvaara S, Ojalakarlsson P, Kallio A, Koulu M 1991. Plasma 3,4-Dihydroxyphenylglycol(Dhpg)and 3-Methoxy-4-Hydroxyphenylglycol(Mhpg)AreInsensitiveIndicatorsofAlpha-2-AdrenoceptorMediatedRegulationofNorepinephrineReleaseinHealthy-HumanVolunteers.LifeSci 49(1):75-84.

[0471] Watson AW, Okello EJ, Brooker HJ, Lester S, McDougall GJ, Wesnes KA 2019. The impact of blackcurrant juice on attention, mood and brain wave spectral activity in young healthy volunteers. Nutr Neurosci 22(8):596-606.

[0472] Yeung AWK, Georgieva MG, Atanasov AG, Tzvetkov NT 2019. Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. Front Mol Neurosci 12.

Claims

1. Use of ophiopogon glycoside or its ester for inhibiting monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B).

2. Use of ophiopogonis glycoside or its ester for preventing or treating diseases or conditions associated with MAO-A or MAO-B enzyme activity, or for maintaining or improving non-clinical cognitive states or conditions associated with MAO-A or MAO-B enzyme activity.

3. The use according to claim 1, wherein the cyperus rotundus or its ester is in a plant material, an extract or a composition.

4. Use according to claim 2, wherein the plant material is blackcurrant (Ribes nigrum).

5. The use according to claim 1, wherein the cyperus rotundus or its ester provides reversible MAO inhibition.

6. The use according to claim 1, wherein the scutellaria baicalensis ester is selected from the group consisting of nigromatine-p-coumarate, nigromatine caffeate and / or nigromatine ferulate and their derivatives.

7. The use according to claim 1, wherein the extract is a polar fraction or component extracted from a selected source of clematis glycoside or its ester.

8. A composition formulated as a food or beverage, a pharmaceutical composition, a nutraceutical, or an extract from a plant material, wherein when the composition is used to inhibit monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B), the composition comprises cyperus rotundus or an ester thereof.

9. The composition of claim 6, wherein the amount of cyperus rotundus in the composition is at least 0.005 mg / g.

10. The composition of claim 6, wherein the amount of cyperus rotundus in the composition is about 0.005 to 70 mg / g.

11. Use of ophiopogon glycoside or its ester, or plant materials, extracts or compositions containing them, in the manufacture of a medicament for inhibiting monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B) in a person in need thereof.

12. The use according to claim 10, for treating or preventing a disease or condition associated with MAO-A or MAO-B enzyme activity in a human in need thereof.

13. The use according to claim 10, for improving, maintaining or preventing mood, anxiety, social anxiety, fatigue, cognitive performance or function, motor performance, attention / alertness, calmness, mental clarity, executive function, working memory, secondary memory, mood, stress, stress reactivity, or for providing a nootropic effect.

14. A method for inhibiting monoamine oxidase A (MAO-A) and / or monoamine oxidase B (MAO-B), the method being performed by administering an effective amount of cyperus rotundus or its ester, or a plant material, extract or composition containing the same, to a person in need thereof.

15. The method of claim 14 for treating or preventing any disease or condition associated with MAO-A or MAO-B enzyme activity.

16. The method of claim 14, for improving, maintaining or preventing a non-clinical outcome selected from the group consisting of mood, anxiety, social anxiety, fatigue, cognitive performance or function, motor performance, attention / alertness, calmness, mental clarity, executive function, working memory, secondary memory, mood, stress, stress reactivity, nootropic effects, and combinations thereof.

17. The use according to any one of claims 11 to 13 or the method according to any one of claims 14 to 16, wherein the use or method modulates, maintains or increases a neurotransmitter selected from the group consisting of dopamine, serotonin, adrenaline and tyramine.

18. The use according to claim 12 or the method according to claim 15, wherein the disease or condition is any neurological or psychiatric condition or affliction associated with MAO-A or MAO-B enzyme activity.

19. The use according to claim 12 or the method according to claim 15 or 16, wherein the disease or condition is selected from the group consisting of depression, atypical depression, panic, social anxiety, bipolar disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), adult ADHD, Alzheimer's disease, dementia, Parkinson's disease and Huntington's disease.

20. The use or method according to any one of claims 11 to 19, wherein for non-clinical use, the daily dose of clematisin or its ester is at least 1 mg, and more preferably 1 to 20 mg.

21. The use or method according to any one of claims 11 to 19, wherein for clinical use the daily dose of clematisin or an ester thereof is at least 20 mg.

22. The use or method according to any one of claims 11 to 19, wherein for clinical use, the daily dose of clematisin or its ester is 20 to 200 mg, or for clinical use, more preferably 20 to 80 mg.

23. A blackcurrant fruit, blackcurrant juice, blackcurrant extract or isolate comprising an effective amount of calendula glycoside or an ester thereof when used to inhibit MAO-A or MAO-B.